Wednesday Research Poster Presentations

POSTER SESSION V: Poster Display Hours – 8:45-13:45
Poster Author Discussion Hour – 12:45-13:45

POSTER SESSION V:
PRM: RESEARCH ON METHODS ROWS A-J
PIH: INDIVIDUAL’S HEALTH ROWS J-M
PND: NEUROLOGICAL DISORDERS ROWS M-P
<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRM1–PRM27</td>
<td>A682</td>
<td>Research on Methods – Clinical Outcomes Methods:</td>
</tr>
<tr>
<td>PRM28–PRM48</td>
<td>A687</td>
<td>Research on Methods – Cost Methods:</td>
</tr>
<tr>
<td>PRM49–PRM67</td>
<td>A691</td>
<td>Research on Methods – Databases &amp; Management Methods:</td>
</tr>
<tr>
<td>PRM68–PRM135</td>
<td>A694</td>
<td>Research on Methods – Modeling Methods:</td>
</tr>
<tr>
<td>PRM136–PRM204</td>
<td>A706</td>
<td>Research on Methods – Patient-Reported Outcomes Studies:</td>
</tr>
<tr>
<td>PRM205–PRM221</td>
<td>A718</td>
<td>Research on Methods – Statistical Methods:</td>
</tr>
<tr>
<td>PRM222–PRM242</td>
<td>A721</td>
<td>Research on Methods – Study Design:</td>
</tr>
<tr>
<td>PRM243–PRM285</td>
<td>A725</td>
<td>Research on Methods – Conceptual Papers:</td>
</tr>
<tr>
<td>PIH1–PIH9</td>
<td>A732</td>
<td>Individual's Health – Clinical Outcomes Studies:</td>
</tr>
<tr>
<td>PIH10–PIH26</td>
<td>A734</td>
<td>Individual's Health – Cost Studies:</td>
</tr>
<tr>
<td>PIH27–PIH74</td>
<td>A737</td>
<td>Individual's Health – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
</tr>
<tr>
<td>PIH75–PIH92</td>
<td>A745</td>
<td>Individual's Health – Health Care Use &amp; Policy Studies:</td>
</tr>
<tr>
<td>PND1–PND16</td>
<td>A748</td>
<td>Neurological Disorders – Clinical Outcomes Studies:</td>
</tr>
<tr>
<td>PND17–PND64</td>
<td>A751</td>
<td>Neurological Disorders – Cost Studies:</td>
</tr>
<tr>
<td>PND65–PND80</td>
<td>A760</td>
<td>Neurological Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
</tr>
<tr>
<td>PND81–PND101</td>
<td>A763</td>
<td>Neurological Disorders – Health Care Use &amp; Policy Studies:</td>
</tr>
</tbody>
</table>
RESEARCH ON METHODS - Clinical Outcomes Methods

PRM1 A1 CART ANALYSIS AS A TOOL TO DETERMINE OPTIMAL TREATMENT INTENSIFICATION TIME IN DIABETES
Flynn A\textsuperscript{1}, Farquhar R\textsuperscript{1}, Das R\textsuperscript{2}, Watson L\textsuperscript{3},\textsuperscript{1}Exploritics Ltd, Belfast, UK, \textsuperscript{2}Merck Sharp & Dohme Limited, Hoddesdon, UK, \textsuperscript{3}Explore-Epi Ltd, Mattishall, UK

PRM2 A2 HOW TO CONDUCT ECONOMIC EVALUATIONS OF NEW TREATMENTS FOR ADVANCED CANCER WHEN OVERALL SURVIVAL DATA ARE NOT AVAILABLE? RESULTS FROM A SYSTEMATIC LITERATURE REVIEW
Beauchemin C\textsuperscript{1}, Lapierre M\textsuperscript{1}, Letarte N\textsuperscript{1}, Yelle L\textsuperscript{4}, Lachaine J\textsuperscript{1}, \textsuperscript{1}University of Montreal, Montreal, QC, Canada, \textsuperscript{2}Centre Hospitalier de l’Université de Montréal – Hôpital Notre-Dame, Montreal, QC, Canada

PRM3 A3 SELECTION OF STATISTICAL APPROACH IN UNDERSTANDING THE ROLE OF CONTRAST MEDIA IN INPATIENT INTERVENTIONAL CARDIOVASCULAR PROCEDURES
David G\textsuperscript{1}, Johnson M\textsuperscript{2}, Lim L\textsuperscript{3}, Mallow PJ\textsuperscript{4}, \textsuperscript{1}The Wharton School, University of Pennsylvania, Philadelphia, PA, USA, \textsuperscript{2}GE Healthcare, Chalfont St Giles, UK, \textsuperscript{3}GE Healthcare, Marlborough, MA, USA, \textsuperscript{4}CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA

PRM4 A4 A STUDY ON CYTOGENETIC AND MOLECULAR ANALYSIS OF PRESENILIN 1 (PS1) GENE IN ALZHEIMER’S DISEASE
Mohana Devi S\textsuperscript{1}, Sasikala K\textsuperscript{2}, Balachandar V\textsuperscript{4}, Dankook University, Chungnam, South Korea, \textsuperscript{3}Bharathiar University, Coimbatore, India

PRM5 A5 HOW GOOD ARE PHYSICIANS AND CHART REVIEWS AT CAPTURING HEALTH RESOURCES AND DRUG UTILISATION BY PATIENTS? RESULTS OF THE PGRX-3 PROSPECTIVE REAL WORLD DATASET VALIDATION STUDY
Grimaldi-Bensouda L\textsuperscript{1}, Rossignol M\textsuperscript{2}, Worsfold A\textsuperscript{3}, Nordon C\textsuperscript{4}, Abenhaim L\textsuperscript{5}, \textsuperscript{1}LASER Research, Paris, France, \textsuperscript{2}McGill University, Montreal, QC, Canada, \textsuperscript{3}LASER Analytica, London, UK

PRM6 A6 THE ACCEPTANCE OF MORBIDITY ENDPOINTS IN THE AMNOG PROCESS IN GERMANY: ARE THERE GREATER HURDLES FOR SUBSTANCES WITHIN ONCOLOGY?
Bakker K, Volmer T, SmartStep Consulting GmbH, Hamburg, Germany

PRM7 A7 COMPARISON OF TREATMENT-RELATED ADVERSE EVENTS RECORDED IN ADMINISTRATIVE CLAIMS DATA WITH THOSE RECORDED IN ELECTRONIC MEDICAL RECORDS FOR MULTIPLE MYELOMA PATIENTS
Irwin DE\textsuperscript{1}, Varker H\textsuperscript{2}, Truven Health Analytics, Chapel Hill, NC, USA, \textsuperscript{3}Truven Health Analytics, Bethesda, MD, USA

PRM8 A8 NON-COMPARATIVE TRIALS TO SUPPLEMENT NETWORK META-ANALYSES USING ARM-SPECIFIC META-REGRESSION: AN APPLICATION TO COMBINATION THERAPIES IN HIV
Kanters S\textsuperscript{1}, Druyts E\textsuperscript{2}, Jansen JP\textsuperscript{3}, Mills EJ\textsuperscript{4}, Thorlund K\textsuperscript{5}, \textsuperscript{1}Redwood Outcomes, Vancouver, BC, Canada, \textsuperscript{2}University of British Columbia, Vancouver, BC, Canada, \textsuperscript{3}Redwood Outcomes, San Francisco, CA, USA, \textsuperscript{4}Stanford University, Stanford, CA, USA

PRM9 A9 CRITICAL APPRAISAL OF REAL WORLD EVIDENCE – A REVIEW OF RECOMMENDED AND COMMONLY USED TOOLS
Quigley JM\textsuperscript{1}, Thompson JC\textsuperscript{2}, Halfpenny NJ\textsuperscript{2}, Scott DA\textsuperscript{3}, EPI Health Economics and Epidemiology, Oxford, UK, \textsuperscript{2}ICON Health Economics, Oxford, UK

PRM10 A10 DOES ATTRITION IN SUBJECT-BASED STUDIES OF DRUG SAFETY LEAD TO BIAS RELATED TO MORBIDITY?
Pignot M\textsuperscript{1}, Kliment A\textsuperscript{2}, Pisa G\textsuperscript{1}, Potthoff P\textsuperscript{3}, Kantar Health, Munich, Germany, \textsuperscript{4}Kantar Health Germany, Munich, Germany, \textsuperscript{5}Kantar Health, Munich, Germany

PRM11 A11 ESTIMATION OF THE PROGRESSION OF COLON CANCER BY JAPANESE LARGE-SCALE INSURANCE BENEFITS DATA ANALYSIS
Iwasaki K\textsuperscript{1}, Arata H\textsuperscript{1}, Soeda J\textsuperscript{2}, Yanai T\textsuperscript{3}, Hiroi S\textsuperscript{4}, Milliman, Tokyo, Japan, \textsuperscript{1}Takeda Pharmaceutical Company Limited, Tokyo, Japan, \textsuperscript{2}Takeda Pharmaceutical Company Ltd., Tokyo, Japan

PRM12 A12 BEYOND THE MIDDLE: EVALUATING SURROGACY OF CLINICAL TRIAL ENDPOINTS ACROSS TRIAL DURATIONS
Wasserman M\textsuperscript{1}, Amin A\textsuperscript{2}, Double Helix Consulting, New York, NY, USA, \textsuperscript{3}Double Helix Consulting, London, UK

PRM13 A13 NETWORK META-ANALYSIS OF MULTIPLE OUTCOMES INCORPORATING DOSE-RELATED CONSTRAINTS: APPLICATION TO OVERACTIVE BLADDER SYNDROME
Owen RK, Tincello DG, Bujkiewicz S, Abrams K, University of Leicester, Leicester, UK

PRM14 A14 THE VALUE OF PROGRESSION-FREE SURVIVAL (PFS) AS AN ENDPOINT IN ONCOLOGY TRIALS
Quinn C\textsuperscript{1}, Palmer S\textsuperscript{2}, Bruns J\textsuperscript{3}, Grant C\textsuperscript{1}, Sykes D\textsuperscript{4}, Kaura S\textsuperscript{5}, PRMA Consulting, Fleet Hampshire, UK, \textsuperscript{3}University of York, Heslington, York, UK, \textsuperscript{4}German Cancer Society, Berlin, Germany, \textsuperscript{5}PRMA Consulting, Hampshire, UK, \textsuperscript{6}Celgene Corporation, Summit, NJ, USA

PRM15 A15 STAKEHOLDER VIEWS ON THE ACCEPTABILITY OF REAL-WORLD EVIDENCE FOR INFORMING TRIAL DESIGN AND ASSESSMENT OF RELATIVE EFFECTIVENESS OF NEW MEDICINES
PRM16  A16  KNOWLEDGE AND AWARENESS OF BREAST CANCER AMONG YOUNG WOMEN LIVING IN SOUTH INDIA
Nirojini P S, Nadendla R, Chalapathi Institute of Pharmaceutical Sciences, Guntur, India

PRM17  A17  ANALYSIS OF EVIDENCE DATA ABOUT ADDING SUCCINIC ACID TO THE VARIOUS MEDICINES
Leleka M 1, Zalis’ka O 1, Paparyha V 2, Kozyr G 2, Danylyuk B 3, Danylko Halytsky Lviv National Medical University, Lviv Ukraine, 2Kyiv National Economic University, Kyiv, Ukraine, 3Ternopil State Medical University, Ternopil, Ukraine

PRM18  A18  OBJECTIVE DATA IN PARKINSON’S DISEASE THERAPY MANAGEMENT – A RETROSPECTIVE ANALYSIS OF THE PARKINSON’S KINETIGRAPH (PKG) DATABASE
Horne M 1, McGregor S 2, Lynch P 3, Zoellner Y 4, 1University of Melbourne, Parkville, Victoria, Australia, 2St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia, 3Global Kinetics Corp., Melbourne, Victoria, Australia, 4Hamburg University of Applied Sciences, Hamburg, Germany

PRM19  A19  MACHINE LEARNING FOR IDENTIFYING POTENTIALLY UNDIAGNOSED POST-STROKE SPASTICITY PATIENTS IN UNITED KINGDOM
Cox A 1, Raluy-Callado M 1, Wang M 1, Bakheit A 2, Moor AP 3, Dinet J 4, Evidera, London, UK, 2Moseley Hall Hospital, Birmingham, UK, 3The Walton Centre NHS Foundation Trust, Liverpool, UK, 4IPSEN Pharma, Boulogne-Billancourt, France

PRM20  A20  PANGAEA 2.0: STATE OF THE ART MULTIPLE SCLEROSIS PATIENT MANAGEMENT IN DAILY CLINICAL PRACTICE. A NEW 3-YEAR OBSERVATIONAL STUDY OF PATIENTS RECEIVING FINGOLIMOD
Ziemssen T 1, Kern R 1, Cornelissen C 1, 1University Clinic Carl Gustav Carus, Dresden, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany

PRM21  A21  TIME RATIOS OR HAZARD RATIOS: ACCELERATING TOWARD A NEW APPROACH?
Padihar A, Parker C, Quigley JM, Mealing S, Scott DA, ICON Health Economics and Epidemiology, Oxford, UK

PRM22  A22  THE USE OF REAL WORLD EVIDENCE (RWE) TO INVESTIGATE THE OVERALL TREATMENT EFFECTS OF DIFFERENT LINES OF THERAPY IN RHEUMATOID ARTHRITIS
Martina R, Jenkins D, Bujkiewicz S, Dequen P, Abrams K, University of Leicester, Leicester, UK

PRM23  A23  OUTCOMES USED IN CLINICAL STUDIES IN ADULT HEMATOLOGY: TEN YEARS OF PUBLICATIONS IN PUBMED
Rosselli D 1, Diaz CE 2, Gutiérrez L 3, 1Pontificia Universidade Javeriana, Bogotá, Colombia, 2Pontificia Universidad Javeriana, Bogotá, Colombia

PRM24  A24  PATIENT VERSUS GENERAL POPULATION HEALTH STATE VALUATIONS: A CASE STUDY OF LOW BACK PAIN
van Dongen JM 1, van den Berg B 1, Bekkering GE 2, van Tulder MW 1, Ostelo RW 1, VU University Amsterdam, Amsterdam, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3KU Leuven, Leuven, Belgium

PRM25  A25  STOCHASTIC MULTICRITERIA ACCEPTABILITY ANALYSIS IN A BAYESIAN FRAMEWORK
Wang H, Celgene International, Boudry, Switzerland

PRM26  A26  MULTIVARIATE NETWORK META-ANALYSIS: AN EXAMPLE IN TYPE 2 DIABETES FOR THE ANALYSIS OF GLYCAEMIC CONTROL
Taieb V 1, Belhadi D 1, Gauthier A 1, Pacou M 2, Amaris, London, UK, 3Amaris, Paris, France

PRM27  A27  A NOVEL ITC APPROACH: MATCHING PATIENT-LEVEL DATA TO STUDY-LEVEL SUMMARY MEANS AND VARIANCES
Alsop JC 1, Regnier SA 2, Wright JJ 1, Numerus, Wokingham, UK, 2Novartis Pharma, Basel, Switzerland

RESEARCH ON METHODS - Cost Methods

PRM28  A28  COMPARISON OF DIFFERENT COSTING METHODS
Wang H 1, Aas E 2, Roman E 3, Smith A 4, University of York, York, UK, 2University of Oslo, Oslo, Norway

PRM29  A29  VIAL SIZES OF PHARMACEUTICALS FOR INFUSION – THE POTENTIAL FOR COST REDUCTIONS AND REDUCED WASTAGE BY OPTIMISING FILL VOLUMES
Porter J 1, Latimer N 2, Lee D 3, Hatswell AJ 4, BresMed, Sheffield, UK, 2University of Sheffield, Sheffield, UK, 3University College London, London, UK

PRM30  A30  METHOD COMPARISON OF CENSORING COST ANALYSES
Wang H 1, Aas E 2, Roman E 3, Smith A 4, University of York, York, UK, 2University of Oslo, Oslo, Norway

PRM31  A31  A COMPARISON OF FAT GRAFTING METHODS ON OPERATING ROOM EFFICIENCY AND COST
Gabriel A 1, Champaneria MC 2, Macarios D 3, Griffin L 4, 1Maxwell GP 5, PeaceHealth Medical Group, Vancouver, WA, USA, 2LifeCell, an Acelity company, Bridgewater, NJ, USA, 3Acelity, San Antonio, TX, USA, 4Loma Linda University Medical Center, Loma Linda, CA, USA

PRM32  A32  CONSISTENCY IN SEARCH STRATEGIES FOR SYSTEMATIC LITERATURE REVIEWS IN NICE SUBMISSIONS
PRM33 A33 IDENTIFICATION OF ITEMS FOR A STANDARDISED RESOURCE-USE MEASURE: REVIEW OF CURRENT INSTRUMENTS
Thorn JC¹, Ridyard CH², Riley R¹, Brookes S¹, Hughes D¹, Wordsworth S³, Noble S¹, Hollingworth W¹,¹University of Bristol, Bristol, UK, ²Bangor University, Bangor, UK, ³University of Oxford, Oxford, UK

PRM34 B1 QUANTIFYING THE COST AND QUALITY OF LIFE IMPLICATIONS OF ADVERSE EVENTS ASSOCIATED WITH LONG-TERM ORAL CORTICOSTEROID USE
Tilden D, Makino K, Cottrell S, Needham M,THEMA Consulting Pty Ltd, Pyrmont, Australia

PRM35 B2 COMPARING COST-EFFECTIVENESS OF EMERGING DRUGS IN ADVANCED CANCER WITHOUT HAZARD RATIOS FOR PROGRESSION
Wiecek W¹, Karcher H¹, Nikodem M²,¹LASER Analytica, London, UK, ²LASER Analytica, Krakow, Poland

PRM36 B3 INCLUDING HUMAN RESOURCE CONSTRAINTS IN HEALTH ECONOMIC EVALUATIONS
Thongkong N, van Baal P, Severens JL,Erasmus University, Rotterdam, The Netherlands

PRM37 B4 MULTIPLE TO SINGLE TRANSITION PROBABILITY: HCV-BASED EXAMPLE
Leleu H, Blachier M,PUBLIC HEALTH EXPERTISE, Paris, France

PRM38 B5 THE COST OF THE NEW ANTIVIRAL THERAPIES AGAINST THE HEPATITIS C VIRUS
Kocsis T, Papp E, Nemeth B, Juhasz J, National Institute of Pharmacy and Nutrition, Budapest, Hungary

PRM39 B6 RESOURCE USE MEASUREMENT IN TRIALS CONDUCTED IN CARE HOMES: A STUDY OF LEVEL-OF-AGREEMENT BETWEEN DATA COLLECTED FROM GP RECORDS AND CARE HOME RECORDS
Sach T¹, Desborough J¹, Houghton J², Holland R², University of East Anglia, Norwich, UK, ²University of East Anglia, Norwich, UK

PRM40 B7 ARE QALYS AN APPROPRIATE MEASURE TO USE WHEN EVALUATING PUBLIC HEALTH INTERVENTIONS IN THE UK?
Taylor M, Filby A, York Health Economics Consortium, York, UK

PRM41 B8 BUDGET IMPACT ANALYSIS IN THE UK SETTING – KNOW YOUR AUDIENCE

PRM42 B9 STRUCTURE OF HEALTH-RELATED DIRECT COSTS IN UKRAINE - THE FIRST STEP OF ANALYSIS
Tolubaiev V¹, Zaliska O¹, Solodkovskyy Y², Irychny H³, Piniazhko O¹, Danylo Halutsky Lviv National Medical University, Lviv, Ukraine, ²Kyiv National Economic University named after Vadam Hetman, Kyiv, Ukraine, ³Ukrainian Center for Scientific Medical Information and Patent License of Ministry of Health of Ukraine, Kyiv, Ukraine

PRM43 B10 CONSTRUCTION OF SIMULATION TECHNIQUES FOR DEVELOPMENT OF OPTIMAL CERVICAL CANcer SCREENING STRATEGIES: EXPERIENCE OF UKRAINE
Soloviev S¹, Artemchuk H², Kovalyuk O¹, Dzyublyk I¹, Dutchak i¹, PL Shypky National medical academy of postgraduate education, Kyiv, Ukraine, ²The National Technical University of Ukraine “Kyiv Polytechnic Institute”, Kyiv, Ukraine

PRM44 B11 THE ECONOMIC IMPACT OF SHAPE FORMULA FOR THE CHILDREN OF OVERWEIGHT AND OBESE MOTHERS
Marsh K¹, Moller J¹, Basarir H¹, Detzel P², Evidera, London, UK, ³Nestlé Research Center, Lausanne, Switzerland

PRM45 B12 DIFFERENT MODELS FOR DIFFERENT PAYERS – ARE WE MOVING TOWARDS OR AWAY FROM UNIVERSAL ECONOMIC MODELS?
Gani R, Lauks S, Blogg K, Quintiles, Reading, UK

PRM46 B13 BAYESIAN ECONOMETRIC MODELLING OF OBSERVATIONAL DATA FOR COST-EFFECTIVENESS ANALYSIS
Saramago Goncalves P¹, Welton NJ², Claxton K¹, Soares M¹, University of York, Heslington, York, UK, ²University of Bristol, Bristol, UK

PRM47 B14 SOCIETAL BURDEN AND IMPACT ON HEALTH RELATED QUALITY OF LIFE (HRQOL) OF NON-SMALL CELL LUNG CANcer (NSCLC) IN EUROPE
Enstone A¹, Panter C¹, Manley Daumont M², Miles R¹, Adelphi Values Ltd, Bollington, UK, ²Bristol-Myers Squibb, Paris, France

PRM48 B15 ESTIMATING LIFETIME MEDICAL COSTS FROM CENSORED CLAIMS DATA
Hwang J¹, Hu T¹, Lee Lj², Wang J³, Academia Sinica, Taipei, Taiwan, ²National Health Research Institutes, Miaoli, Taiwan, ³National Cheng Kung University College of Medicine, Tainan, Taiwan

RESEARCH ON METHODS - Databases & Management Methods

PRM49 B16 COMPARISON OF COMORBIDITY MEASURES TO PREDICT ECONOMIC OUTCOMES IN A LARGE UK PRIMARY CARE DATABASE
Bessou A¹, Guelfucci F², Aballea S², Toumi M³, Poole C⁴, National School For Statistics and Information Analysis (ENSAI), BRUZ, France, ²Creativ- Ceutical, Paris, France, ³Aix-Marseille University, Marseille, France, ⁴Astellas Pharma Europe Ltd, Chertsey, UK

PRM50 B17 EFFECT OF FINGOLIMOD ON DISEASE PROGRESSIONS, RELAPSE RATE AND BRAIN ATROPHY IN MULTIPLE SCLEROSIS PATIENTS: REVIEW OF LITERATURE AND PHARMACOECONOMIC CONSIDERATIONS
Rosselli D¹, Castañeda-Cardona C², Lasalvia P², Otálora M³, Karpf E⁴, Márquez A⁵, Mejía N⁶, Pontificia Universidade
Javeriana, Bogotá, Colombia, ²Pontificia Universidad Javeriana, Bogota, Colombia, ³Novartis Colombia, Bogotá, D.C., Colombia

PRM51 B18 ONCOLOGY LITERATURE BANK FOR CANCERS AND THERAPIES FOR HEOR: CONCEPT AND UTILIZATION OF ONCOLITBANK
Gala S, Shah A, Nanavaty M, Mwamburi M, Market Access Solutions LLC, Raritan, NJ, USA

PRM52 B19 GENERATING COSTING ALGORITHMS FOR ONCOLOGY DRUGS USING ADMINISTRATIVE DATABASES
Mittmann N, ¹Seung SJ, Cheng SY, Liu N, Camacho X, Maclagan L, DeAngelis C, Earle C, Sunnybrook Research Institute, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Odette Cancer Centre, Toronto, ON, Canada, ⁴Ontario Institute for Cancer Research, Toronto, ON, Canada

PRM53 B20 “BIG DATA” IN ALZHEIMER’S DISEASE RESEARCH: AN ENVIRONMENTAL SCAN
Hong Y, Pickering MK, ¹Perfecto EM, Albrecht J, Ung B, Yang K, Lederer H, ¹University of Maryland, School of Pharmacy, Baltimore, MD, USA, ²University of Maryland, School of Medicine, Baltimore, MD, USA

PRM54 B21 PHARMACEUTICAL PRODUCTS AND VACCINES DISCUSSED IN SOCIAL MEDIA: WHICH ONES ARE PATIENTS TALKING ABOUT?
Bell HG, Schifano L, Rodriguez H, Pierce C, Dasgupta N, ¹Shaikh S, Powell GE, ¹GSK, RTP, NC, USA, ²Epidemico, Boston, MA, USA, ³GSK, Uxbridge, NC, USA

PRM55 B22 HUNTING FOR RANDOMISED CONTROLLED TRIALS (RCTS): A COMPARISON OF SEARCH FILTERS DESIGNED TO IDENTIFY RCTS
Steves S, Buchanan-Hughes AM, Evans J, Leonard S, Costello Medical Consulting Ltd, Cambridge, UK

PRM56 B23 INDIRECT TREATMENT COMPARISON (ITC) TO DEMONSTRATE THE UTILITY OF ONCOLITBANK: AN ONCOLOGY LITERATURE REGISTRY
Gala S, Shah A, Nanavaty M, Mwamburi M, Market Access Solutions LLC, Raritan, NJ, USA

PRM57 B24 UTILITY AND METRICS OF NATURAL LANGUAGE PROCESSING ON IDENTIFYING PATIENTS FOR PHARMACOEPIEMIOLOGIC STUDIES
Bailey N, Wilson A, ¹Kamauu A, DuVall S, Anolinx, Murray, UT, USA, ²VA Salt Lake City Health Care System, Salt Lake City, UT, USA

PRM58 B25 METHODOLOGICAL DIFFICULTIES OF COMPLIANCE ANALYSES BASED ON REAL-WORLD DATA

PRM59 B26 REVIEW OF COMORBIDITY MEASURES TO PREDICT ECONOMIC OUTCOMES IN REAL-LIFE DATABASE STUDIES
Guelfucci F, Besouw A, Aballea S, ¹CreativCeutical, Paris, France, ²National School For Statistics and Information Analysis (INSAI), BRUZ, France

PRM60 B27 THE PEDIATRIC ASTHMA PATIENT REGISTRY IN IMPLEMENTATION OF LONG TERM FOLLOW UP

PRM61 B28 THE NATIONALWIDE OSMED HEALTH-DB DATABASE. A TOOL TO SUPPORT HEALTHCARE DECISION-MAKING AND REAL-WORLD EVIDENCE GENERATION
Degli Esposti L, Saragoni S, Sangiorgi D, Buda S, Cangini A, Russo P, ¹Clicon S.r.l., Ravenna, Italy, ²Italian Medicines Agency (AIFA-Agenzia Italiana del Farmaco), Roma, Italy

PRM62 B29 DEVELOPMENT OF AN INTERNATIONAL OBSERVATIONAL STUDY PROGRAMME TO DESCRIBE THE MANAGEMENT AND OUTCOMES OF MILD STROKE AND TRANSIENT ISCHAEMIC ATTACK IN ROUTINE CLINICAL PRACTICE

PRM63 B30 HEALTH TECHNOLOGY ASSESSMENT NEEDS INFORMATION TECHNOLOGY: THE EXPERIENCE FROM THE FIRST ITALIAN STUDY ON THE DA VINCI SURGICAL ROBOT
Manetti S, Palla I, Freschi C, Cuschiéri A, Turchetti G, ¹Scuola Superiore Sant’Anna, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³University of Dundee, Dundee, UK

PRM64 B31 MANAGEMENT OF SOFT TISSUE SARCOMA (STS) IN FRANCE - A RETROSPECTIVE ANALYSIS OF THE FRENCH CLINICAL BIOLOGICAL SARCOMA DATABASE (GSF-GETO)
Longin J, Merck Serono, Lyon, France

PRM65 B32 THE REMOTE MONITORING TECHNOLOGIES IN THE PATIENT RISK MANAGEMENT
Namazova-Baranova L, ¹Vishneva E, Antonova E, Smirnov V, Suvorov R, Smirnov I, Molodchenkov A, ¹Scientific Centre of Children Health, Moscow, Russia, ²The Institute for system analysis of Russian Academy of Sciences, Moscow, Russia

PRM66 B33 USING MACHINE LEARNING TO POPULATE A MARKOV MODEL BY MINING BIG DATA DIRECTLY FROM HOSPITAL EHRs – AN APPLICATION TO DYNAMICALLY PREDICT HOSPITAL-ACQUIRED PRESSURE ULCERS
Padula W, Makic MB, Epstein Z, Gemmell J, Mishra MK, Meltzer D, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ²University of Colorado, Aurora, CO, USA, ³Pomona College, Claremont, CA,
RESEARCH ON METHODS - Modeling Methods

PRM68  C2  GENERALIZED IMPLEMENTATION OF EM ALGORITHM FOR ESTIMATION OF TRANSITION PROBABILITY MATRIX
Gupta S1, Chattopadhyay S2, Gunda P1, Novartis Healthcare Pvt. Ltd., Hyderabad, India, Indian Statistical Institute, Kolkata, India

PRM69  C3  PATIENT HETEROGENEITY IN COST-EFFECTIVENESS MODELS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): ARE CURRENT MODELS SUITABLE TO EVALUATE PERSONALIZED MEDICINE

PRM70  C4  MODELING THE BURDEN OF ABDOMINAL AORTIC ANEURYSM (AAA) IN EUROPE IN 2013
Stuntz M1, Deerefield Institute, New York, NY, USA

PRM71  C5  COST-EFFECTIVENESS OF ESCALATING TO NATALIZUMAB OR SWITCHING AMONG IMMUNOMODULATORS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
Furneri G1, Santoni L2, Ricella C2, Prosperini L3, EMBA Consulting, Melegnano, Italy, Biogen, Milan, Italy, Department of Neurology and Psychiatry - Sapienza University, Rome, Italy, Roma, Italy

PRM72  C6  CONTRASTING PREDICTIONS OF CARDIOVASCULAR INCIDENCE DERIVED FROM ALTERNATIVE RISK PREDICTION MODELS IN TYPE 1 DIABETES
McEwan P1, Foos V2, Lamotte M3, Health Economics and Outcomes Research Ltd, Monmouth, UK, IMS Health, Basel, Switzerland, IMS Health, Vilvoorde, Belgium

PRM73  C7  VALIDATION OF A MARKOV MODEL FOR ECONOMIC EVALUATION OF SCREENING AND PREVENTIVE INTERVENTIONS IN ALZHEIMER’S DISEASE IN DENMARK
Sopina E1, Martikainen JA2, Spackman E3, Sørensen J1, University of Southern Denmark, Odense, Denmark, University of Eastern Finland, Kuopio, Finland, University of York, Heslington, York, UK

PRM74  C8  CONTRASTING MODEL PREDICTED LIFE EXPECTANCY IN PATIENTS WITH TYPE 2 DIABETES ACROSS DIFFERENT MORTALITY RISK PREDICTION MODELS VERSUS DATA FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM
McEwan P1, Foos V2, Lamotte M3, Health Economics and Outcomes Research Ltd, Monmouth, UK, IMS Health, Basel, Switzerland, IMS Health, Vilvoorde, Belgium

PRM75  C9  THE EFFICIENCY PATH: AN ESTIMATION OF COST-EFFECTIVENESS THRESHOLDS FOR 185 COUNTRIES BASED ON PER CAPITA HEALTH EXPENDITURES AND LIFE EXPECTANCY
Pichon-Riviere A1, Augustovski F1, Garcia Marti S1, Caporale J1, IECS-Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

PRM76  C10  HOW TO HANDLE LEVELS OF EVIDENCE IN HEALTH ECONOMIC MODELLING
Nuijten M1, Krol M1, Redekop WK2, Ars Accessus Medica, Jisp, The Netherlands, Merck Serono, Schiphol-riijk, The Netherlands, Erasmus University Rotterdam, The Netherlands

PRM77  C11  BEST PRACTICES FOR NETWORK META-ANALYSIS METHODOLOGY: COMPARATIVE EFFECTIVENESS OF INTERFERON-BETA THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
Beckerman R1, Locklear JC2, Jiang Y3, Solon C4, Smith NJ5, Phillips AL6, Maple Health Group, LLC, New York, NY, USA, EMD Serono, Inc., Rockland, MA, USA, CBPartners, New York, NY, USA, CBPartners, San Francisco, CA, USA

PRM78  C12  REVIEW OF ECONOMIC MODELS FOR THE EVALUATION OF BIOLOGIC DMARDS IN RHEUMATOID ARTHRITIS
Van Laer J1, Gubbels L1, Rodriguez IL2, Maervoet T3, Nielsen AT4, Peterson S5, Hemels M6, Ganguy R7, Janssen Pharmaceutica N.V., Beerse, Belgium, Quintiles Advisory Services, Hoofddorp, The Netherlands, Quintiles Consulting, Reading, UK, Quintiles Consulting, Vilvoorde, Belgium, Janssen-Cilag A/S, Birkerød, Denmark, Janssen, Horsham, PA, USA, GlaxoSmithKline, King of Prussia, PA, USA

PRM79  C13  INVESTIGATING THE IMPACT OF STRUCTURAL CHANGES IN A NICE SINGLE TECHNOLOGY APPRAISAL COST-EFFECTIVENESS MODEL
Alam MF1, Barton P2, Monahan M3, Swansea University, Swansea, UK, University of Birmingham, Birmingham, UK

PRM80  C14  INVESTIGATING THE VALUE OF PATIENT LEVEL DATA TO INFORM ESTIMATES OF ADPKD PROGRESSION GENERATED WITHIN THE ADPKD OUTCOMES MODEL
McEwan P1, Bennett H1, O’Reilly K1, Robinson P2, Health Economics and Outcomes Research Ltd, Monmouth, UK, Health Economics and Outcomes Research Ltd, Cardiff, UK, Otsuka Pharmaceutical Europe Ltd, Wexham, UK
COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL-FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
Furneri G, Santoni L, Marchesi C, Iannazzo S, Cortesi P, Piacentini P, Caputi A, Mantovani LG, CHARTA Foundation, Milano, Italy, 2Biogen, Milan, Italy, 3Biogen Spa, Milan, Italy, 4CESP - Center for Public Health Research, University of Milan Bicocca, Milano, Italy, 5CESP - Center for Public Health Research, University of Milan Bicocca, Monza, Italy, 6University of Messina, Messina, Italy

IMPACT OF UNCERTAINTY IN PREDICTED RISKS ON THE COST-EFFECTIVENESS OF RISK-STRATIFIED PREVENTIVE TREATMENT STRATEGIES
van Giessen A, Piebes M, Koffijberg H, University Medical Center Utrecht, Utrecht, The Netherlands, 2University of Twente, Enschede, The Netherlands

CHALLENGES TO THE ECONOMIC MODELLING OF MACULAR OEDEMA DUE TO RETINAL VEIN OCCLUSION AND DIABETES
Almond C, Brereton N, BresMed, Sheffield, UK

THE IMPORTANCE OF ACCOUNTING FOR BASELINE HYPOGLYCAEMIA FREQUENCY WHEN MODELLING HYPOGLYCAEMIA DISUTILITY IN TYPE 1 DIABETES MELLITUS
McEwan P, Lamotte M, Foos V, Health Economics and Outcomes Research Ltd, Monmouth, UK, 2IMS Health, Vilvoorde, Belgium, 3IMS Health, Basel, Switzerland

VALIDATING APPROACHES TO MODELLING END-STAGE RENAL DISEASE USING THE IMS CORE DIABETES MODEL
McEwan P, Foos V, Lamotte M, 1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2IMS Health, Basel, Switzerland, 3IMS Health, Vilvoorde, Belgium

ADAPTING LITERATURE-BASED REMISSION RATES FOR CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA TO THE NEEDS OF A HEALTH ECONOMIC MODEL: A KAPLAN-MEIER APPROACH
Partha G, Gupta S, Bhattacharyya S, Halliday A, McBride D, Graham J, Baip M, Marsland A, Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharmaceuticals UK Limited, Surrey, UK, 3Rti Health Solutions, Manchester, UK, 4Rti Health Solutions, Research Triangle Park, NC, USA, 5Novartis Pharma AG, Basel, Switzerland, 6The University of Manchester, Salford Royal Hospital, Salford, UK

EXPERT PERSPECTIVE ON THE TREATMENT OF FUNCTIONAL DYSPEPSIA AND MOTILITY DISORDERS: A MULTI-CRITERIA DECISION ANALYSIS USING THE ANALYTIC HIERARCHY PROCESS (AHP)
Mühlbacher AC, Kaczynski A, Hochschule Neubrandenburg, Neubrandenburg, Germany

THE IMPACT OF BASELINE HBA1C AND HBA1C TRAJECTORIES ON TIME TO THERAPY ESCALATION IN TYPE 2 DIABETES MELLITUS
McEwan P, Foos V, Lamotte M, 1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2IMS Health, Basel, Switzerland, 3IMS Health, Vilvoorde, Belgium

VALIDATION OF FRACTURE RISK MODEL IN JAPANESE WOMEN COMPARED WITH FRAX
Moriwaki K, Noto S, Kobe Pharmaceutical University, Kobe, Japan, 2Niigata University of Health and Welfare, Niigata, Japan

DEVELOPMENT AND VALIDATION OF A CONCEPTUAL MODEL OF MULTIPLE MYELOMA
Gonzalez-McQuire S, Campion M, Bennison C, Xu W, Pantiri K, Hensen M, Weisel K, Terpos E, Knop S, Amgen (Europe) GmbH, Zug, Switzerland, 2Pharmmerit Ltd, Heslington, UK, 3Pharmmerit BV, Rotterdam, The Netherlands, 4University Hospital of Tübingen, Tübingen, Germany, 5University of Athens School of Medicine, Athens, Greece, 6University Hospital of Würzburg, Würzburg, Germany

DEVELOPMENT OF A COST-EFFECTIVENESS ANALYSIS FRAMEWORK FOR MODELING TREATMENT OF ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT
Roth JA, Cohen J, Veenstra DL, Chen E, Jhuti GS, Neumann PJ, Sullivan SD, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA, 3University of Washington, Seattle, WA, USA, 4Genentech, South San Francisco, CA, USA, 5Roche, Basel, Switzerland, 6Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

A COMPARISON OF DISCRETE EVENT SIMULATION (DES) VERSUS MARKOV MODELS WITH A PRACTICAL APPLICATION TO HUMAN-IMMUNODEFICIENCY VIRUS (HIV)
Gillies H, Abacus International, Bicester, UK

SELECTING EVIDENCE-BASED PREVENTIVE TREATMENT THRESHOLDS BY OPTIMIZING PREFERRED OUTCOMES
van Giessen A, de Wit GA, Moons C, Koffijberg H, University Medical Center Utrecht, Utrecht, The Netherlands, 2National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 3University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands

MODELING TREATMENT SEQUENCES IN HEALTH TECHNOLOGY ASSESSMENTS
Zheng Y, Pan F, Sorensen S, Evidera, Bethesda, MD, USA

BUDGET IMPACT ANALYSIS OF CEREBROLYSIN IN THE TREATMENT OF ACUTE ISCHEMIC STROKE OF MODERATE AND SEVERE DEGREES OF SEVERITY IN THE RUSSIAN FEDERATION
Kulikov A, Abdarashitova G.I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PRM96 C30 A COMPARISON OF THREE SURVIVAL MODELS TO ESTIMATE THE COST-EFFECTIVENESS OF CANCER IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED MELANOMA
Bohensky M1, Gorelik A2, Kim H3, Liew D1, Melbourne University, Parkville, Australia, 2Royal Melbourne Hospital, Parkville, Australia, 3Bristol-Myers Squibb Australia, Mulgrave, Australia

PRM97 C31 ECONOMIC AND CLINICAL IMPACT OF SECONDHAND SMOKING IN KOREA
Lee J, Lee Y, Bae S,Ewha Womans University, Seoul, South Korea

PRM98 C32 INVESTIGATING THE IMPACT OF CONTEMPORARY RISK FACTORS FOR DIABETES COMPLICATIONS AND THEIR EVOLUTION ON RISK PREDICTION USING THE UKPDS 82 EQUATIONS
McEwan P1, Foos V2, Lamotte M1, Health Economics and Outcomes Research Ltd, Monmouth, UK, 1IMS Health, Basel, Switzerland, 2IMS Health, Vilvoorde, Belgium

PRM99 C33 BETTER REIMBURSEMENT DECISION-MAKING BASED ON EXPECTED COST-EFFECTIVENESS: USING VALUE OF INFORMATION DECISION ANALYSIS TO IMPROVE THE DESIGN AND EFFICACY OF A PHASE III PROGRAM FOR ERLOTINIB
Mukherjee SC1, Latimer N2, Richards P3, Nixon RM4, Hall PS5, Pharmerit International, York, UK, 1University of Sheffield, Sheffield, UK, 2Novartis Pharma AG, Basel, Switzerland, 3University of Edinburgh, Edinburgh, UK

PRM100 D1 MODELING THE NATURAL HISTORY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS: A NEW MODELING APPROACH USING DISCRETE EVENT SIMULATION
Hernandez L1, Guo S2, Altincatal A3, Naoshy S4, Watson C4, Evidera, Lexington, MA, USA, 1Biogen, Cambridge, MA, USA

PRM101 D2 IMPLEMENTATION OF POPULATION DYNAMICS IN MODELLING HEALTH AND BUDGET IMPACT OF AN INTERVENTION FOR A CHRONIC DISEASE WITH MULTIPLE DISEASE SUBTYPES
Tran-Duy A1, Boonen A2, Caro JF3, Severens JL4, Maastricht University Medical Center+, Maastricht, The Netherlands, 1Evidera, Lexington, MA, USA, 2Erasmus University Rotterdam, Rotterdam, The Netherlands

PRM102 D3 BUDGET IMPACT ANALYSIS OF DELAYED-RELEASE DIMETHYLFUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
Furneri G1, Marchesi C2, Santoni L3, EBMA Consulting, Melegnano, Italy, 2Biogen Spa, Milan, Italy, 3Biogen, Milan, Italy

PRM103 D4 QUANTITATIVE ASSESSMENT OF THERAPEUTIC VALUE OF INNOVATIVE MEDICAL TECHNOLOGIES: METHODOLOGY AND PRELIMINARY RESULTS
Khachatryan GR1, Rebrova OY2, Omelyanovskiy VV3, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, 1Pirogov Russian National Research Medical University, Moscow, Russia, 2Center of HTA, Moscow, Russia

PRM104 D5 EIGHT WAYS TO IMPROVE THE INTERPRETATION AND REPORTING OF COST-EFFECTIVENESS ANALYSES OF SCREENING INTERVENTIONS
O’Mahony JF, Trinity College Dublin, Dublin, Ireland

PRM105 D6 IMPACT OF GREXIT ON PHARMACEUTICAL PRICING: AN INTERNATIONAL REFERENCE PRICING ANALYSIS
Weiss J1, Hakim P2, Kjeldgaard-Pedersen J3, Degun R4, Walsh K5, Navigant Consulting Inc, London, UK, 1data2impact, Copenhagen, Denmark, 2GSK, Middlesex, UK

PRM106 D7 DEVELOPMENT OF A CONCEPTUAL MODEL OF MULTIPLE MYELOMA FOR USE IN ECONOMIC MODELLING: A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY THE EVIDENCE BASE
Gonzalez-McQuire S1, Campioni M1, Bennison C2, Xu W3, Pantiri K4, Hensen M5, Weisel K6, Terpos E7, Knop S8, Amgen (Europe) GmbH, Zug, Switzerland, 2Pharmerit Ltd, Heslington, UK, 3Pharmerit BV, Rotterdam, The Netherlands, 4University Hospital of Tübingen, Tübingen, Germany, 5University of Athens School of Medicine, Athens, Greece, 6University Hospital of Würzburg, Würzburg, Germany

PRM107 D8 SIMULATING INDIVIDUAL PATIENT LEVEL DATA USING AN ILLNESS-DEATH MODELLING FRAMEWORK IN ORDER TO ADJUST FOR TREATMENT SWITCHING WHEN ONLY SUMMARY DATA ARE AVAILABLE
Boucher R1, Abrams K, Lambert P, University of Leicester, Leicester, UK

PRM108 D9 MARKOV MODELING OF HIV INFECTION IN RUSSIAN POPULATION
Sukhorukikh OA1, Rebrova OY2, The Russian Academy of National Economy and Public Administration, Moscow, Russia, 1Pirogov Russian National Research Medical University, Moscow, Russia

PRM109 D10 VERIFICATION AND VALIDATION OF HEALTH ECONOMIC MODELS FOR DIABETES
Boye KS1, Lage ME2, Lage MJ3, Valentine WP1, Pollock RF2, Saunders R2, 1Eli Lilly and Company, Indianapolis, IN, USA, 2HealthOutcomes Research, LLC, Bonita Springs, FL, USA, 3Ossian Health Economics and Communications GmbH, Basel, Switzerland

PRM110 D11 IMPACT OF POVERTY ON MULTIDIMENSIONAL INFANT MORTALITY RATE IN BRAZIL
Araujo JA1, Silva AF2, Wichmann R3, 1Federal University of Ceará, Fortaleza, Brazil, 2Brazilian Ministry of Health, Brasilia, Brazil

PRM111 D12 THE ROLE OF PATIENT LEVEL DATA IN ASSESSING HEALTH ECONOMIC VALUE: A CASE STUDY USING EDGE AND THE CORE DIABETES MODEL
PRM112 D13  SURGERY AS AN OUTCOME IN COST-EFFECTIVENESS ANALYSIS
Murphy D, Vlachaki I, Guy H, WG Access Ltd, London, UK

PRM113 D14  TIMED AUTOMATA MODELING OF THE PERSONALIZED TREATMENT DECISIONS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Schivo S, Degeling K, Koffijberg H, IJzerman MJ, Langerak R, University of Twente, Enschede, The Netherlands

PRM114 D15  COST-EFFECTIVENESS ANALYSIS OF SCHIZOPHRENIA TREATMENT WITH HALOPERIDOL, OLANZAPINE AND RISPERIDONE IN BOSNIA AND HERCEGOVINA, REPUBLIC OF SRPSKA BY APPLICATION OF THE MARKOV MODEL
Vulijicic Z, Hemofarm d.o.o. Banja Luka, Banja Luka, Bosnia

PRM116 D16  REVIEWING THE COST-EFFECTIVENESS OF CHEMOTHERAPY AND TARGETED THERAPY FOR METASTATIC BREAST CANCER
Pouwelse XG, Ramaekers BL, Joore MA, Maastricht University Medical Center+, Maastricht, The Netherlands

PRM117 D17  DECISION-ANALYTIC MODELING STUDIES: AN OVERVIEW FOR CLINICIANS USING DLBCL AS AN EXAMPLE
Bardia A, Garg G, ValueResearch Systems, Hyderabad, India, 2ValueResearch Systems, Burgdorf, Germany

PRM118 D18  ZRX MCDM: A FULLY FLEXIBLE TOOL TO SUPPORT THE LOCAL ADAPTATION OF MULTIPLE-CRITERIA DECISION CRITERIA IN HEALTH CARE
Zah V, Thompson S, Berjan M, Goeree R, ZRx Outcomes Research, Mississauga, ON, Canada, 2ZRx Outcomes Research, Berlin, Germany, 3ZRx Outcomes Research USA LLC, Rancho Cucamonga, CA, USA, 4McMaster University, Hamilton, ON, Canada

PRM119 D19  PATENT EXPIRY AND GENERIC PRICING: THE IMPACT ON COST-EFFECTIVENESS RESULTS
Hirst A, Murphy D, Vlachaki I, WG Access Ltd, London, UK

PRM120 D20  MODEL-BASED TECHNIQUES IN THE EARLY PHASES OF THE MEDICAL DEVICE DEVELOPMENT: A SYSTEMATIC LITERATURE REVIEW
Manetti S, Turchetti G, Scuola Superiore Sant'Anna, Pisa, Italy

PRM121 D21  ASSESSMENT OF HEALTH-ECONOMICS DECISION MODELS IN INTERVENTION STUDIES OF SEASONAL INFLUENZA AND BREAST CANCER
de Boer PT, Frederix GW, Al MJ, Feenstra TF, Verner P, 1University of Groningen, Groningen, The Netherlands, 2Utrecht University, Utrecht, The Netherlands, 3Erasmus University, Rotterdam, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands

PRM122 D22  SENSITIVITY ANALYSIS: HOW MUCH IMPACT DOES IT HAVE ON THE NICE DECISION MAKING PROCESS?
Hirst A, Guy H, Murphy D, WG Access Ltd, London, UK

PRM123 D23  HOW TO MODEL SURVIVAL IN COST-EFFECTIVENESS ANALYSIS? DIFFERENCES BETWEEN MARKOV AND PARTITIONED SURVIVAL ANALYSIS MODELS

PRM124 D24  PHYSICIANS’ CHOICE AS A COMPARATOR IN CLINICAL TRIALS: CHALLENGES FOR PHARMACOECONOMIC MODELLING OF INNOVATIVE TREATMENTS TO SUPPORT HEALTH TECHNOLOGY ASSESSMENTS
Mbanya Z, Madrigal AM, Wright A, PHMR Ltd, London, UK

PRM125 D25  EVALUATION OF THE EFFECT OF CRUDE LEAVES EXTRACT OF INDIGOFERA SPICATA FORSSK. (FABACEAE) ON BLOOD GLUCOSE LEVEL OF NORMOGLYCEMIC, ORAL GLUCOSE LOADED AND ALLOXAN INDUCED DIABETIC RODENTS
Birru EM, University of Gondar, Gondar, Ethiopia

PRM126 D26  DISEASE PROGRESSION IN RHEUMATOID ARTHRITIS: KEY ELEMENT FOR COST-EFFECTIVENESS MODELLING
Hummel N, Gsteiger S, University of Bern, Bern, Switzerland, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland

PRM127 D27  THE FUTILITY OF COST-EFFICACY ANALYSIS
Elbasha EH, Cook J, Merck & Co., Inc., Kenilworth, NJ, USA

PRM128 D28  THE LIMITATIONS OF ICERS IN SCREENING INTERVENTIONS AND THE RELATIVE NET BENEFIT ALTERNATIVE
O'Mahony JP, Trinity College Dublin, Dublin, Ireland

PRM129 D29  COST-EFFECTIVENESS ANALYSIS OF CEREBROLYSIN IN THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE MODERATE AND SEVERE DEGREES OF SEVERITY IN THE RUSSIAN FEDERATION
Kulikov A, Abdursaitova G, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PRM130 D30  USING MACHINE LEARNING TO DETECT PATIENTS WITH UNDIAGNOSED RARE DISEASES: AN APPLICATION OF SUPPORT VECTOR MACHINES TO A RARE ONCOLOGY DISEASE
Rigg J, Lodhi H, Nasuti P, IMS Health, London, UK
Weinblatt M, Emery P
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH IMPROVEMENTS IN PATIENT REPORTED OUTCOMES FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY


Weinblatt M, Leeds University, Leeds, UK, Johns Hopkins University, Baltimore, MD, USA, Universitätsmedizin Hamburg, Germany
**PRM144 E11**  
**CULTURAL ADAPTATION INTO SPANISH (SPAIN) OF THE QUESTIONNAIRE “OVERACTIVE BLADDER - FAMILY IMPACT MEASURE (OAB-FIM)”**

Arlandis-Guzmán S1, Martínez-Cuenca E1, Martínez-García R2, Bonillo-García M3, Brosota-Rico E4, **Rejas J5**, Hospital Universitario La Fè, Valencia, Spain, 4Hospital Universitario Clínico Valencia, Valencia, Spain, 5Pfizer, Alcobendas, Spain

**PRM145 E12**  
**DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE ASSESSING THE FEARS AND BELIEFS OF PATIENTS SUFFERING FROM CHRONIC RHEUMATIC DISEASES**

**Gossec L1**, Saraux A2, Hudry C2, Mathore-Philibert F3, Poussière M4, de Chalus T5, Russo-Marie F6, Joubert J7, Chauvin P8, Berenbaum F9, Sorbonne Universités, Université Pierre et Marie Curie, AP-HP, Hôpital Pitie Salpêtrière, Paris, France, 2CHU de la Cavale-Blanche, Brest Cedex, France, 3AP-HP Hôpital Cochin, Paris, France, 4Independent Researcher, Paris, France, 5UCB Pharma, Colombes, France, 6Arthritis Fondation Courtin, Neuilly-sur-Seine, France, 7UCB Pharma, Paris, France, 8French National Institute of Health and Medical Research (INSERM), Paris, France, 9Sorbonne Universités, Université Pierre et Marie Curie, AP-HP, Hôpital Saint-Antoine, Paris, France

**PRM146 E13**  
**A VALIDITY AND RELIABILITY STUDY OF THE POVERTY RELATED QUALITY OF LIFE QUESTIONNAIRE IN A TURKISH PATIENT POPULATION**

**Yilmaz F1**, Numanoglu Tekin R2, Malhan S3, 1Baskent University, ankara, Turkey, 2Baskent University, Ankara, Turkey

**PRM147 E15**  
**DEVELOPMENT OF A PREDICTION MODEL OF DISEASE ACTIVITY IN SUPPORT OF CLINICAL PRACTICE – THE ACRODAT EXPERIENCE**

**Pfll A1**, van der Lely AJ2, Badia X3, Brue T4, Buchfelder M5, Burman P6, Ghigo E7, Gomez R8, Jorgensen JO9, Lugener A10, van der Lans-Bussemaker J11, Pfizer, Inc, San Diego, CA, USA, 2Erasmus University Medical Center, Rotterdam, The Netherlands, 3University of Barcelona, Barcelona, Spain, 4Centre de Recherche Neurobiologie Neurophysiologie, Marseille, France, 5Universitätsklinikum Erlangen, Erlangen, Germany, 6Skåne University Hospital, Malmo, Sweden, 7Univ Degli Studi Di Torino, Torino, Italy, 8Pfizer, Inc, Tadworth/Surrey, UK, 9Aarhus University, Aarhus, Denmark, 10Medical University of Vienna, Vienna, Austria, 11Hospital Sant Pau, Barcelona, Spain, 12Charité Universitätsmedizin, Berlin, Germany

**PRM148 E15**  
**PHYSICAL FUNCTIONING AND PAIN IN CHRONIC LOW BACK PAIN: A SYSTEMATIC REVIEW OF PSYCHOMETRIC PROPERTIES OF VARIOUS OUTCOMES MEASURES**

**Kanukula R1**, Vsn M2, Ganji K3, Likhar N1, Dang A2, 1MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India, 2MarksMan Healthcare Solutions, Navi Mumbai, India

**PRM149 E16**  
**QUALITY OF LIFE INSTRUMENTS USED TO MEASURE JOB-RELATED STRESS: A SYSTEMATIC REVIEW**

**Han A1**, Bae S2,Ewha Womans University, Seoul, South Korea

**PRM150 E17**  
**COMPARISON OF TWO METHODS FOR ESTIMATION OF WORK LIMITATION SCORES FROM HEALTH STATUS MEASURES**

**Anatchkova M1**, Fang H2, Kiri N3, Ware J4, Björner JB5, 1University of Massachusetts Medical School, WORCESTER, MA, USA, 2University of Copenhagen, Copenhagen, Denmark

**PRM151 F1**  
**QUALITY OF LIFE ISSUES IMPORTANT TO PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES**

**Salek S1**, Kamudoni P2, Oliva E3, Ionova T4, 1University of Hertfordshire, Hatfield, UK, 2Institute for Medicines Development, Cardiff, UK, 3Hematology Unit, Reggio Calabria, Italy, 4Multinational Center for Quality of Life Research, St Petersburg, Russia

**PRM152 F2**  
**VALUATION OF THE EQ-5D-5L WITH COMPOSITE TIME TRADE-OFF FOR THE GERMAN POPULATION**

**Klose K1**, Graf von der Schulenburg J2, Greiner W1, 1School of Public Health, Bielefeld University, Bielefeld, Germany, 2Leibniz Universität Hannover, Hannover, Germany

**PRM153 F3**  
**MEASURING THE IMPACT OF MULTIPLE SCLEROSIS: ENHANCING THE PERFORMANCE OF THE MSIS-29 AND MSWS-12**

**Cano S1**, Cleanthous S1, Marquis P2, Hobart J3, Naoshy S4, Mikol D5, Petrillo J6, Steiner D7, Watson C8, 1Modus Outcomes, Stotfold, UK, 2Modus Outcomes, Newton, MA, USA, 3Plymouth University, Plymouth, Devon, UK, 4Biogen, Cambridge, MA, USA

**PRM154 F4**  
**IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY**

**Emery P1**, Bingham C2, Burmester GR3, Bykerk VP4, Furst D5, Mariette X6, Purcaru O7, VanLunen B8, Weinblatt M9, Leeds University, Leeds, UK, 1Johns Hopkins University, Baltimore, MD, USA, 2Universitätsmedizin Berlin, Berlin, Germany, 3Hospital for Special Surgery, New York, NY, USA, 4UCLA, Los Angeles, CA, USA, 5Paris-Sud University, Paris, France, 6UCB Pharma, Brussels, Belgium, 7UCB Pharma, Durham, NC, USA, 8Brigham and Women's Hospital, Boston, MA, USA

**PRM157 F6**  
‘HOW DOES THAT MAKE YOU FEEL?’ - THE AMBIGUITY OF TRANSLATING DEPRESSION

**Williams H1**, Welbeck E2,ICON Plc, Oxford, UK

**PRM158 F7**  
**THE IMPACT OF SEVERE ASTHMA ON THE QUALITY OF LIFE: A SYSTEMATIC REVIEW**
PRM159 F8 ASSESSING THE TRANSLATABILITY OF THE TERM “DISTRESSED”
Talbert M¹, Brandt B², McKown S², Gawlicki M²,¹Corporate Translations Inc, Chicago, IL, USA, ²Corporate Translations Inc, East Hartford, CT, USA

PRM160 F9 CONTENT VALIDITY OF THE CURRENT HEALTH SATISFACTION QUESTIONNAIRE (CHES-Q) AMONG PEOPLE LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) AND COMORBID CHRONIC KIDNEY DISEASE (CKD)
Traina SB¹, McQuarrie K¹, Barrett A², DiBenedetti D², McLeod L², ¹Janssen Global Services, LLC, Raritan, NJ, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA

PRM161 F10 DEMONSTRATING METHODS FOR HANDLING MISSING PATIENT REPORTED OUTCOME (PRO) DATA IN CLINICAL TRIAL DATA ANALYSIS
Nixon MJ, Nixon A, Chilli Consultancy, Salisbury, UK

PRM162 F11 QUALITATIVE EQUIVALENCE BETWEEN PAPER AND EDIARY VERSIONS AND USABILITY OF 4 PRO QUESTIONNAIRES FOR UTERINE FIBROIDS
Eremenco S¹, Stringer S¹, Gleeson S¹, Landrain A¹, Falcon i², Evidera, Inc., Bethesda, MD, USA, ²AbbVie, North Chicago, IL, USA

PRM163 F12 WHEN IS IT EVENING, WHEN IS IT NIGHT? WHY IT IS CHALLENGING TO TRANSLATE TIMES OF THE DAY IN CLINICAL TRANSLATIONS

PRM165 F13 EXTERNAL VALIDITY OF THE WELL-BEING RELATED TO FOOD QUESTIONNAIRE (WELL-BFQ©): VARIATIONS ACCORDING TO THE SUBJECTS’ NUTRITIONAL STATUS
Allaert FA¹, Ginon E¹, Rogeaux M², Urdapilleta I², Capuron L², Dupuy A², Layé S², Lecerf J², Prost M², Guillemin I¹, Marrel A¹, Arnould B¹, ¹CEN Biotech/CEN Nutriment, Dijon, France, ²Laboratory for Experimentation in Social Sciences and Behavioral Analysis (LESSAC) ESC, Dijon, France, ³DANONE Nutricia Research, Palaiseau, France, ⁴Social Psychology Laboratory of Paris (LAPPS EA 4386), Saint-Denis, France, ⁵Laboratory of Nutrition and Integrative Neurobiology - NutriNeuro; INRA UMR 1286, Bordeaux, France, ⁶CERTOP UMR CNRS 5044, Toulouse, France, ⁷INRA UMR 1286, Bordeaux, France, ⁸Institut Pasteur de Lille, Lille, France, ⁹LARA SPIRAL, Couternon, France, ¹⁰Patient-Centered Outcomes - Mapi, Lyon, France

PRM166 F14 METHODS TO ACCOUNT FOR FOLLOW-UP TIME DIFFERENCES WHEN CALCULATING QALYS FROM RANDOMISED CONTROLLED TRIALS
Alshreef A¹, Spackman E², ¹University of Shefffield, Sheffield, UK, ²University of York, Heslington, York, UK

PRM167 F15 VALIDATION OF A SHORT "OCCUPATIONAL DISABILITY INDEX" AS A MEASURE FOR DISEASE IMPACTS ON WORK PERFORMANCE AND OCCUPATIONAL HANDICAPS
Pisa G¹, Pignot M¹, Potthoff P¹, ¹Kantar Health, Munich, Germany, ²Kantar Health, Munich, Germany

PRM168 F16 SURVEY OF NEUROLOGIST’S CURRENT PRACTICES IN EVALUATION OF MULTIPLE SCLEROSIS TO IDENTIFY DOMAINS FOR A NEW CLINICIAN-REPORTED MEASURE
Phillips GA¹, ²Matza LS², Stewart KD², Coyne KS², Malley K¹, ²Biogen Idec Inc., Cambridge, MA, USA, ³Evidera, Bethesda, MD, USA

PRM169 F17 PSYCHOMETRIC VALIDATION OF THE MULTIDIMENSIONAL DYSPNEA PROFILE (MDP) QUESTIONNAIRE
Gilet H¹, Pignier C², Aguilaniu B³, Devillier P⁴, Didier A³, Perez T⁴, Similowski T⁵, Morélot-Panzini C⁶, ¹Patient-Centered Outcomes - Mapi, Lyon, France, ²Pierre Fabre Médicament, Castres, France, ³Université Joseph Fourier, Grenoble, France, ⁴UPRES EA220, Hôpital Foch, Suresnes, France, ⁵Pôle des Voies Respiratoires, Hôpital Larrey, CHU de Toulouse, Toulouse, France, ⁶Clinique des Maladies Respiratoires, Centre Hospitalier Régional et Universitaire de Lille, Lille, France, ⁷AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Foix, Service de Pneumologie et Réanimation Médicale, Paris, France, ⁸Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR1158, Paris, France

PRM170 G1 HOW FRENCH SUBJECTS DESCRIIBE WELL-BEING FROM FOOD AND EATING HABITS? DEVELOPMENT, AND SCORING DEFINITION OF THE WELL-BEING RELATED TO FOOD QUESTIONNAIRE (WELL-BFQ©)
Guillemin I¹, Marrel A¹, Arnould B¹, Capuron L², Dupuy A², Ginon E², Layé S², Lecerf J², Prost M², Rogeaux M², Urdapilleta I², Allaert FA¹, ¹Patient-Centered Outcomes - Mapi, Lyon, France, ²Laboratory for Experimentation in Social Sciences and Behavioral Analysis (LESSAC) ESC, Dijon, France, ³DANONE Nutricia Research, Palaiseau, France, ⁴Social Psychology Laboratory of Paris (LAPPS EA 4386), Saint-Denis, France, ⁵Laboratory of Nutrition and Integrative Neurobiology - NutriNeuro; INRA UMR 1286, Bordeaux, France, ⁶CERTOP UMR CNRS 5044, Toulouse, France, ⁷INRA UMR 1286, Bordeaux, France, ⁸Institut Pasteur de Lille, Lille, France, ⁹LARA SPIRAL, Couternon, France, ¹⁰CEN Biotech/CEN Nutriment, Dijon, France

PRM171 G2 MEASURING PREFERENCE-BASED PATIENT BENEFIT OF MEDICAL DEVICES: A NEW INSTRUMENT FOR HEALTH ECONOMIC ASSESSMENTS
Lesén E, Björholt I, Ingelgård A, Olson F, ¹Nordic Health Economics, Gothenburg, Sweden

PRM172 G3 MODELLING METHODS FOR EQ-5D – A FITTING TIME FOR CHANGE
Reddy B¹, Adams R², Barry M¹, Kind P², Walsh C¹, Salomon J³, ¹National Centre for Pharmacoeconomics, Dublin, Ireland, ²HSE University, St Petersburg, Russia, ³University of Limerick, Limerick, Ireland, ⁴Harvard University, Boston, MA, USA
PRM173 G4 DEVELOPMENT OF A DISCRETE CHOICE EXPERIMENT TO ASSESS PATIENTS’ AND PROFESSIONALS’ PREFERENCES FOR HOME ENTERAL NUTRITION
Olveira G1, Martínez Olmos MA2, Fernández de Bobadilla B3, Ferrer M4, Virgili N5, Vega B6, Blanco M7, Layola M8, Lizán L9, Tribaldos de Suarez M10, Hospital Regional Universitario de Málaga, Málaga, Spain, 1Hospital Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 2Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 3Hospital Clínico Universitario Virgen de Arrixaca de Murcia, Murcia, Spain, 4Hospital Bellvitge, Barcelona, Spain, 5Hospital Universitario Ramón y Cajal, Madrid, Spain, 6Nestle health science, Barcelona, Spain, 7Outcomes 10, Castellon, Spain

PRM174 G5 MEASURING THE IMPACT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN THE ASCEND TRIAL: EQUATING THE MSIS-29, MSWS-12, ABILHAND-56 AND SF-36
Cano S1, Cleanthous S1, Marquis P2, Hobart J3, Naoshy S4, Mikol D5, Petrolli J6, Steiner D7, Watson C8, Modus Outcomes, Stockfot, UK, 1Modus Outcomes, Newton, MA, USA, 2Plymouth University, Plymouth, Devon, UK, 3Biogen, Cambridge, MA, USA

PRM175 G6 WHAT DO WE MEAN WHEN WE TALK ABOUT “U.S. SPANISH”?
Towns L1, Cassedy C2, Johnson H3, Anderson H4, ICON Plc, Oxford, UK, 1ICON Plc, Durham, UK, 2ICON PLC, Oxford, UK

PRM176 G7 DEVELOPMENT OF A PREFERENCE-BASED INSTRUMENT: COMPARED WITH EQ-5D
Park J1, Ahn J1, Jo M2, Shin S3, Suh J4, Cho S5, Ock M6, Lee H7, National Evidence based Health-care Collaborating Agency, Seoul, South Korea, 1University of Ulsan College of Medicine, Seoul, South Korea

PRM177 G8 ASSESSMENT OF CONTENT EQUIVALENCE AND USABILITY BETWEEN THE PAPER AND ELECTRONIC VERSIONS OF THE PSORIASIS SYMPTOM AND SIGN DIARY (PSSD) AMONG SUBJECTS WITH PLAQUE PSORIASIS
Eremenco S1, McQuarrie K2, Brooks A1, Landrian A3, Maguire S4, Shepherd P5, Han C6, Evidera, Inc., Bethesda, MD, USA, 2Janssen Global Services, LLC, Raritan, NJ, USA, 3ERT, Boston, MA, USA

PRM178 G9 DEVELOPING AND VALIDATING A NEW TOOL: PHYSICIANS’ BARRIERS, ATTITUDES AND PRACTICES TOWARDS APPLYING SMOKING CESSATION INTERVENTIONS IN THEIR CLINICS
Albarooodi KA1, Syed Sulaiman SA2, Awaisu A3, Shafie AA4, Lajis R5, Abo-Maal M6, Universiti Sains Malaysia, Penang, Malaysia, 2Universiti Sains Malaysia, Pulau Pinang, Malaysia, 3Qatar University, Doha, Qatar

PRM179 G10 COMPARISON OF A PROFILE AND MULTI PROFILE BEST WORST SCALING TASK: A PREFERENCE STUDY IN PARKINSON'S PATIENTS
Groothuis-Oudshoorn CG1, Weemink MG2, van Til JA3, 1University of Twente, Enschede, The Netherlands, 2University Twente, Enschede, The Netherlands

PRM180 G11 TRANSLATION AND CULTURAL ADAPTATION DIFFICULTIES ENCOUNTERED DURING LINGUISTIC VALIDATION OF THE HABITUAL ACTIVITY ESTIMATION SCALE (HAES)
Welbeck E, Williams H, ICON Plc, Oxford, UK

PRM181 G12 DEVELOPMENT OF AN EQ-5D RESPIRATORY BOLT-ON
Hoogendoorn M1, Boland MR2, Goossens LM3, Oppe M4, Stolk EA5, Rutten van-Molken M6, 1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2University of Oxford, Oxford, UK, 3EuroQol Group, Rotterdam, The Netherlands

PRM182 G13 THE EFFECT OF STRESS AND COPING RESOURCES ON PREDICTING QUALITY OF LIFE OF GRADUATE STUDENTS
Yao G, Wang Y, Chien C, National Taiwan University, Taipei, Taiwan

PRM183 G14 METHOTREXATE ADHERENCE QUESTIONNAIRE: A NEW TOOL TO ASSESS ADHERENCE IN PATIENTS TREATED WITH METHOTREXATE
Dias-Barbosa C1, Guillemin I2, Aassi M3, Bernasconi C4, Brethous M5, Reiss W6, Arnould B7, 1Patient-Centered Outcomes - Mapi, Lyon, France, 2F Hoffmann-La Roche Ltd, Basel, Switzerland, 3University of Alabama at Birmingham, Birmingham, AL, USA

PRM184 G15 THE MOST FREQUENT FEARS AND BELIEFS OF 226 PATIENTS WITH RHEUMATOID ARTHRITIS OR SPONDYLOARTHITIS, USING A NOVEL QUESTIONNAIRE
Gossec L1, Chauvin P2, Hudry C3, Mathoret-Philibert F4, Poussière M5, de Chalus T6, Russo-Marie F7, Joubert J8, Saraux A9, Berenbaum F10, Sorbonne Universités, Université Pierre et Marie Curie, AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 2French National Institute of Health and Medical Research (INSERM), Paris, France, 3AP-HP Hôpital Cochin, Paris, France, 4Independent Researcher, Paris, France, 5UCB Pharma, Colombes, France, 6Arthritis Fondation Courtin, Neuilly-sur-Seine, France, 7UCB Pharma, Paris, France, 8CHU de la Cavale-Blanche, Brest Cedex, France, 9Sorbonne Universités, Université Pierre et Marie Curie, AP-HP, Hôpital Saint-Antoine, Paris, France

PRM185 G16 TOOLS FOR MEASURING WORKABILITY – RESULTS DERIVED FROM LITERATURE AND EXPERT INTERVIEWS
Amler N1, Felder S2, Mau W3, Merkeshal S4, Schöffski O5, 1Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany, 2Universität Basel, Basel, Switzerland, 3Martin-Luther-Universität Halle-Wittenberg, Halle, Germany, 4Medizinische Hochschule Hannover, Hanover, Germany

PRM186 G17 DOES ONE SIZE FIT ALL? - CHALLENGES FACED WHEN ADAPTING TRANSLATIONS FOR AN ELECTRONIC PLATFORM
Amir I1, Felder S2, Mau W3, Merkeshal S4, Schöffski O5, 1Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany, 2Universität Basel, Basel, Switzerland, 3Martin-Luther-Universität Halle-Wittenberg, Halle, Germany, 4Medizinische Hochschule Hannover, Hanover, Germany
PRM187 G18  PATIENT REPORTED OUTCOMES IN THE DEVELOPMENT OF NEW MEDICATIONS FOR TYPE 2 DIABETES: A REVIEW OF RECENTLY APPROVED PRODUCTS
Reaney M, Celeste Elash CA, ERT, Peterborough, UK, ERT, Pittsburgh, PA, USA

PRM188 G19  THE MAPS REPORTING STATEMENT FOR STUDIES MAPPING ONTO GENERIC PREFERENCE-BASED OUTCOME MEASURES

PRM189 G20  TRANSLATION AND LINGUISTIC VALIDATION OF THE CAREGIVER QUALITY OF LIFE CYSTIC FIBROSIS SCALE (CQOLCF) AND THE MULTIDIMENSIONAL SCALE OF PERCEIVED SOCIAL SUPPORT (MSPSS) FOR USE IN GERMANY AND THE UNITED KINGDOM (UK)
Narayanan S, Blondeau W, Zimet GD, Ganser R, Two R, Ipsos Healthcare, Washington, DC, USA, Independent Consultant, Auburn, ME, USA, Indiana University School of Medicine, Indianapolis, IN, USA, PharmaQuest Ltd., Bloxham, UK

PRM190 G21  ASSESSING OUTCOMES FOR COST-UTILITY ANALYSES IN MENTAL HEALTH INTERVENTIONS: COMPARISON OF MULTI-ATTRIBUTE UTILITY INSTRUMENT EQ-5D WITH MENTAL HEALTH SPECIFIC OUTCOMES GHQ12
Feldman I, Lindkvist M, Uppsala University, Uppsala, Sweden, Umeå University, Umeå, Sweden

PRM191 G22  HAPPINESS EFFECTS ON HEALTH-STATE VALUATIONS
Chicaiza Becerra LA, Garcia-Molina M, Universidad Nacional de Colombia, Bogota, Colombia

PRM192 G23  QUALITATIVE EQUIVALENCE BETWEEN PAPER AND EDIARY VERSIONS AND USABILITY OF 6 PRO QUESTIONNAIRES FOR ENDOMETRIOSIS
Eremenco S, Stringer S, Gleeson S, Landrian A, Falcon i, Evidera, Bethesda, MD, USA, AbbVie, North Chicago, IL, USA

PRM193 G24  MAPPING OF THE 16-ITEM SORT FORM VERSION OF THE MENOPAUSE CERVANTES HEALTH-RELATED-QUALITY-OF-LIFE SCALE ONTO THE EQ-5D-3L
Monroy M, Ruíz MA, Rejas J, Sánchez-Borrego R, Coronado PJ, Universidad Autónoma de Madrid, 28049, Spain, Pfizer, Alcobendas, Spain, Clínica DIATROS, Barcelona, Spain, Hospital Clínico San Carlos, Madrid, Spain

PRM194 G25  AVOIDING ANYTHING ‘ABNORMAL’ IN THE TRANSLATION OF ‘USUALLY’
Anderson H, Scharf L, Griffin A, ICON Plc, Oxford, UK

PRM195 G26  MIGRATION OF THE FATIGUE SYMPTOMS AND IMPACTS QUESTIONNAIRE–RELAPSING MULTIPLE SCLEROSIS (FSIQ-RMSTM) FROM PAPER TO AN ELECTRONIC DIARY FORMAT
Eremenco S, Shaffer S, Schüller R, Evidera, Inc., Bethesda, MD, USA, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

PRM196 G27  MONITORED COGNITIVE DEBRIEFING INTERVIEWS: A CASE STUDY
Cole JC, Gawlicki M, Brandt B, McKown S, Talbert M, PPD, San Diego, CA, USA, Corporate Translations Inc, East Hartford, CT, USA, Corporate Translations Inc, Chicago, IL, USA

PRM197 G28  DEVELOPMENT OF A MEASURE TO ASSESS SEVERITY OF MPS II: THE DISEASE SEVERITY SCORE

PRM198 G29  COST ANALYSIS STUDY OF ORAL ANTI-DIABETIC DRUGS AVAILABLE IN INDIAN GOVT GENERIC (JAN AUSHADHI,JEEVANDHARA ) DRUGS AND BRAND DRUGS MARKET IN RURAL / URBAN AREA OF GUNTUR, ANDHRA PRADESH, INDIA
Nallani VR, CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR, India

PRM199 G30  MEASUREMENT INVARIANCE OF THE WHOQOL-OLD MODULE ACROSS DIFFERENT DEMOGRAPHIC GROUPS IN TAIWAN’S ELDERLY PEOPLE
Hsieh P, Yao G, National Taiwan University, Taipei, Taiwan

PRM200 G31  EMPIRICAL EVIDENCE FOR IDENTIFYING BEST PRACTICES IN TRANSLATABILITY ASSESSMENT AS A PROACTIVE TOOL FOR ENHANCING THE QUALITY OF PRO AND HRQOL TRANSLATION AND LINGUISTIC VALIDATION
Tvupa S, Wild D, Jagiellonian University in Kraków, Krakow, Poland, Parkinsons UK, Oxford, UK

PRM201 G32  SOMETHING OLD, SOMETHING BORROWED, SOMETHING NEW: A DIRECT COMPARISON OF THREE QUALITATIVE ELICITATION METHODS

PRM202 G33  ANCHORING BIAS IN TTO VALUATIONS
Garcia-Molina M, Chicaiza Becerra LA, Universidad Nacional de Colombia, Bogota, Colombia

PRM203 H1  PERFORMANCE SCORE EXTRACTION FROM PANEL DATA FOR MULTI-CRITERIA DECISION ANALYSIS (MCDA) USING A REGRESSION-BASED APPROACH
TELEPHONE VERSUS FACE-TO-FACE INTERVIEWS FOR PATIENT-REPORTED OUTCOME INSTRUMENT DEVELOPMENT

Mazar I, Lamoureux R, Ojo O, Kevane G, Banderas B, Stokes J, Shields A, Adelphi Values USA, Boston, MA, USA

RESEARCH ON METHODS - Statistical Methods

INTERPRETING RESULTS FROM BAYESIAN NETWORK META-ANALYSES (NMA): A GUIDE FOR NON-STATISTICIANS


NON-ADHERENCE AND NON-PERSISTENCE SHOULD BE ANALYZED SEPARATELY: THE EXAMPLE OF METHOTREXATE (MTX) THERAPY IN THE THERAPY OF NEWLY TREATED RHEUMATOID ARTHRITIS IN GERMANY

Mueller S, Krueger K, Flacke J, Heinrich H, Fuchs A, Maywald U, Wilke T, IPAM, Wismar, Germany, Praxiszentrum St. Bonifatius, München, Germany, Roche Pharma AG, Grenzach, Germany, AOK PLUS, Dresden, Germany, AOK Plus, Dresden, Germany, Ingress Health, Wismar, Germany

USING TANGENT LINE SEGMENTS TO DETERMINE STATISTICAL DIFFERENCES BETWEEN SURVIVAL CURVES AT A SINGLE POINT IN TIME

Wasser T, Kern DM, Eisenberg D, HealthCore Inc., Wilmington, DE, USA, HealthCore Inc, Wilmington, DE, USA

SIMULATED TREATMENT COMPARISON OF TIME-TO-EVENT (AND OTHER NON-LINEAR) OUTCOMES


THE USE OF INDIRECT COMPARISONS IN MEDICINES EVALUATION FOR THEIR ACCESS TO REIMBURSEMENT BY THE HAS

Guichard M, D’Andon A, Rumeau Pichon C, Borget I, Haute Autorité de Santé, Saint Denis La Plaine, France, Haute Autorité de santé, Saint-Denis La Plaine, France, Institut Gustave Roussy, Villejuif, France

A METHOD BASED ON THE REMAINING VALUE OF PERFECT INFORMATION FOR THE SAMPLE SIZE CALCULATION IN RANDOMIZED TRIAL-BASED COST-EFFECTIVENESS ANALYSES

Bader C, Donadel M, Maillard A, Benard A, University Hospital Bordeaux, Bordeaux, France

DISPROPORTIONALITY MEASURES USED IN SIGNAL DETECTION: AN ASSESSMENT ON PHARMACOVIGILANCE ADVERSE EVENT REPORTING SYSTEM DATA

Quattrini G, Zambon A, Simoni L, Fiori G, University of Milano-Bicocca, Milan, Italy, MEDIDATA SRL, MODENA, Italy, Medineos Observational Research, Modena, Italy

CORRECTING FOR SWITCHING TO SECOND LINE TREATMENT IN THE SURVIVAL ANALYSIS: AN EXAMPLE OF THE USE OF INVERSE PROBABILITY OF CENSORING WEIGHTED ANALYSIS

Sanchez L, Luaces P, Valdés F, Viada C, Cuevas A, Ramos M, Crombet T, Center of Molecular Immunology, Havana, Cuba

THE USE AND ACCEPTANCE OF META-ANALYSIS OF SURVIVAL OUTCOMES TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS IN THE UK


META-ANALYSIS TO SUPPORT TECHNOLOGY SUBMISSIONS TO HEALTH TECHNOLOGY ASSESSMENT AUTHORITIES: CRITICISMS BY NICE AND EVIDENCE REVIEW GROUPS IN THE UK


ALTERNATIVES TO WINBUGS FOR NETWORK META-ANALYSIS

Fleetwood K, Yellowlees A, Stephenson M, Quantics Consulting Ltd, Edinburgh, UK, University of Guelph, Guelph, ON, Canada

USING MACHINE LEARNING TECHNIQUES TO CLASSIFY OECD COUNTRIES ACCORDING TO HEALTH EXPENDITURES

Cinaroglu S, Hacettepe University, Ankara, Turkey

THE USE OF PROPENSITY SCORE MATCHING DOES NOT PROTECT AGAINST REGRESSION ARTIFACTS (REGRESSION TOWARDS THE MEAN)

Caron C, Wasser T, Eisenberg D, Reading Hospital, West Reading, PA, USA, HealthCore Inc., Wilmington, DE, USA

APPLICATION OF SIMPLE IMPUTATION TECHNIQUES FOR MISSING PAIRWISE CONTRASTS FROM MULTI-ARM TRIALS WHEN USING FREQUENTIST NETWORK META ANALYSIS

Petto H, Brnabic A, Kadziola Z, Belger M, Eli Lilly Regional Operations GmbH, Vienna, Austria, Eli Lilly, Sydney, Australia, Eli Lilly and Company Ltd, Windlesham, UK

INDIRECT COMPARISONS IN BENEFIT ASSESSMENT

Kühnast S, Schiffner-Rohe J, Rahnenführer J, Leverkus F, Technical University of Dortmund, Dortmund,
RESEARCH ON METHODS - Study Design

PRM222 H20 TRANSPARENCY AND REPRODUCIBILITY OF SUPPLEMENTARY SEARCH METHODS IN NICE SINGLE TECHNOLOGY APPRAISAL MANUFACTURER SUBMISSIONS
Witkowski MA, Aldhouse N, Abacus International, Bicester, UK

PRM223 H21 INCREASING PRECISION OF REAL-WORLD DATA ESTIMATES: THE IMPORTANCE OF A STEP-WISE PROCESS TO LIMIT DATA COLLECTION ERRORS AND DATA INCOMPLETENESS

PRM224 H22 A COMPREHENSIVE DISEASE MODEL OF POLYCYSTIC OVARY SYNDROME (PCOS)
Eek D1, Paty J2, Black P3, Celeste Elash CA3, Reaney M3, Asta Zeneca, Molndal, Sweden, 2Quintiles, Hawthorne, NY, USA, 3ERT, Pittsburgh, PA, USA, 4ERT, Peterborough, UK

PRM225 H23 EVALUATION OF QUALITY ASSESSMENT TOOLS FOR NON-RANDOMISED CONTROLLED TRIALS ASSESSING SURGICAL INTERVENTIONS: A SYSTEMATIC REVIEW OF SYSTEMATIC REVIEWS
Numatov UB, Xiong T, Kroes MA, Abacus International, Bicester, UK

PRM226 H24 INCIDENCE AND PREVALENCE ESTIMATIONS BASED ON CLAIMS DATA – NEW METHODOLOGICAL CONSIDERATIONS
Prosser C1, Altevers J1, Hickstein L2, Walker J2, Braun S1, Xcenda GmbH, Hannover, Germany, 2Elsevier Health Analytics, Health Risk Institute, Berlin, Germany

PRM227 H25 STATISTICAL ASSESSMENT OF A CASE-FINDING ALGORITHM FOR IDENTIFYING NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN ADMINISTRATIVE CLAIMS DATABASES
Turner RM1, Croft E2, Chen Y1, Tunceili O1, Elesinmogun C2, Fernandes A2, HealthCore, Wilmington, DE, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3HealthCore Inc., Wilmington, DE, USA

PRM228 H26 SYSTEMATIC LITERATURE REVIEW OF ADJUNCTIVE ANTI-EPILEPTIC DRUG TRIALS IN PATIENTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES ILLUSTRATES CHANGES IN STANDARD OF CARE OVER 12-20 YEARS
Tsong WH1, Gomez-Ulloa D2, Li H3, Forsythe A4, Kramer L1, Eisai Inc., Woodcliff Lake, NJ, USA, 2IMS Health, Barcelona, Spain, 3IMS Health, Alexandria, VA, USA

PRM229 H27 DO WE NEED TO STRENGTHEN STUDY DESIGN IN OBSERVATIONAL STUDIES?
Longagnani C1, Simoni L, Fiori GG, Medineos Observational Research, Modena, Italy

PRM230 H28 ECONOMIC STUDY DESIGN FOR THE OPTIMIZE STUDY ON ORBITAL AHERCTOMY AND DRUG-COATED BALLOON DEVICES FOR THE TREATMENT OF BELOW-THE-KNEE PERIPHERAL ARTERIAL DISEASE
Martinsen BJ1, Weber SA2, Pietzsch ML2, Behrens A1, Weatherspoon M1, Iggyarto Z1, Zhao R2, Kotlarz H2, Pietzsch JB2, Cardiovascular Systems, Inc., St. Paul, MN, USA, 2Cellogic GmbH, Berlin, Germany, 3University of Minnesota, Minneapolis, MN, USA, 4Wing Tech Inc., Irvine, CA, USA

PRM232 H29 METHODOLOGICAL CONSIDERATIONS FOR THE IMPLEMENTATION OF A EUROPEAN MANDATED RETROSPECTIVE DRUG UTILISATION STUDY (DUS) TO INVESTIGATE THE USE OF DEXMEDETOMIDINE (DEXDOR®) IN CLINICAL PRACTICE
Stein D1, Weatherall M2, Garratt C2, Aantaa R3, Conti G4, Lewis MA5, Moore N6, Gutthann S7, UBC: An Express Scripts Company, Dorval, QC, Canada, 2Orion Corporation Orion Pharma, Nottingham, UK, 3University of Turku, Turku, Finland, 4Catholic University Institution of Anaesthesiology, Rome, Italy, 5EPES Epidemiology GmbH, Berlin, Germany, 6University of Bordeaux, CHU de Bordeaux, Hospital Pellegrin, Bordeaux, France, 7RTI Health Solutions, Barcelona, Spain

PRM233 H30 TRIAL DESIGN AND MARKET ACCESS IMPLICATIONS: OUTCOMES FROM COMPARATOR CHOICE
Khoury C1, Duque R2, Freiberg M3, Quintiles Consulting, Neu-Isenburg, Germany, 2Quintiles Commercial, Mannheim, Germany

PRM234 H31 THE DIABETES TELEPHONE STUDY: DESIGN AND CHALLENGES OF A PRAGMATIC CLUSTER RANDOMIZED TRIAL TO IMPROVE DIABETIC PERIPHERAL NEUROPATHY TREATMENT
Adams AS1, Bayliss E2, Schmiddiel JA3, Altschuler A4, Dyer W5, Neugebauer R6, Jaffe M7, Young JD8, Grant RW9, Kaiser Permanente Division of Research, Oakland, CA, USA, 2Kaiser Permanente, Denver, CA, USA, 3Kaiser Permanente South San Francisco Medical Center, South San Francisco, CA, USA, 4Kaiser Permanente Oakland Medical Center, Oakland, CA, USA

PRM235 H32 LET'S TALK! IS CHATTER ON SOCIAL MEDIA AMONGST PARTICIPANTS COMPROMISING CLINICAL TRIALS?
RESEARCH ON METHODS - Conceptual Papers

PRM243 I7 REPRESENTING THE THRESHOLD IN THE COST-EFFECTIVENESS PLANE: PROPOSING A NEW GRAPHICAL CONVENTION
O'Mahony JF, Trinity College Dublin, Dublin, Ireland

PRM244 I8 MODELLING HEALTH BENEFITS ASSOCIATED TO EARLY DIAGNOSIS AND TREATMENT OF COPD
Fiorentino F1, Alarçao J1, Bábara C2, Costa J3, Borges M3, Gouveia M4, Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 1Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 2Institute of Molecular Medicine, Lisbon, Portugal, 3Católica Lisbon School of Business and Economics, Lisbon, Portugal

PRM245 I9 HOW TO CALCULATE VALUE OF INFORMATION IN SECONDS USING 'SAVI', THE SHEFFIELD ACCELERATED VALUE OF INFORMATION WEB APP
Strong M, Brennan A, Oakley J, University of Sheffield, Sheffield, UK

PRM246 I10 NORDIC LONGITUDINAL DATA FROM ELECTRONIC MEDICAL RECORDS AND FULL POPULATION NATIONAL REGISTERS: UNIQUE OPPORTUNITIES FOR NEW INSIGHTS IN BENEFIT OF DIABETES PATIENTS
Lindh A1, Persson F2, Sobocki P3, Bodegard J4, Lindarck N5, Österåker Primary Care Center, Åkersberga, Sweden, 1Herlev University Hospital, Herlev, Denmark, 2Pyargus/IMS Health, Stockholm, Sweden, 3AstraZeneca Nordic, Södertälje, Sweden

PRM247 I11 NEW STANDARDS TO DERIVE PREFERENCE-BASED HRQOL VALUES
Krabbe PF, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PRM248 I12 EARLY HEALTH ECONOMIC ASSESSMENT IN INNOVATION PARTNERSHIPS: LESSONS FROM THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING
de Graaf G1, Steuten L2, Pecchia L3, Boehler C4, Panaxea BV, Enschede, The Netherlands, 1University of Washington and Panaxea bv, Seattle, WA, USA, 2University of Warwick, Coventry, UK, 3European Commission, Joint Research Centre, Sevilla, Spain

PRM249 I13 CAPTURING QUALITY OF LIFE (QOL) DATA IN RARE INDICATIONS: CASE STUDY IN RADIODINE-REFRACTORY THYROID CANCER (RR-DTC)
Hudgens S1, Pelletier C2, Forsythe A3, Taylor M4, Clinical Outcomes Solutions, Tucson, AZ, USA, 1Eisai, Woodcliff Lake, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Oregon Health and Science University, Portland, OR, USA

PRM250 I14 FILLING THE GAP BETWEEN RISK/BENEFIT ASSESSMENT FOR DRUGS AND RISK ASSESSMENT FOR CONSUMER GOODS
Hofmann-Xu L, Bonduelle D, Plantör S, IMS Health Germany, Munich, Germany

PRM251 I15 THE POWER OF THE PATIENT VOICE: FORMALISING QUALITATIVE DATA IN THE DRUG APPROVAL PROCESS

PRM252 I16 A PRACTICAL GUIDE TO ADDING PATIENT HETEROGENEITY INTO PHASE III TRIALS: RESULTS FROM IMI GETREAL WP2
Karcher H1, Fu S2, Nordon C3, Efthimiou O4, Schneeweiss S5, Abenhaim L1, 1Laser Analytica, London, UK, 2Laser Analytica, Loerrach, Germany, 3Laser Research, Paris, France, 4University of Ioannina, Ioannina, Greece, 5Harvard
RAPID AND AUTOMATED TEST FOR CONNECTEDNESS OF EVIDENCE NETWORKS IN NETWORK META ANALYSIS
Thom H, Lu G, Bristol University, Bristol, UK

THE NEED TO REVISE DISCOUNT RATES IN BELGIUM, THE NETHERLANDS, POLAND AND THE UK
O'Mahony JE1, Pauluden M1, Trinity College Dublin, Dublin, Ireland, 1University of Alberta, Edmonton, AB, Canada

ESTABLISHING THE COST-EFFECTIVENESS OF GENOMIC-BASED DIAGNOSTIC TESTS: ARE CURRENT METHODS SUFFICIENT AND APPROPRIATE?
Spackman E, Hinde S, Bojke L, Payne K, Sculpher MJ, 1University of York, Heslington, York, UK, 2University of York, Heslington, UK, 3University of Manchester, Manchester, UK

THE CHALLENGES IN EVALUATING THE COST-EFFECTIVENESS OF COMPLEX INTERVENTIONS
Faria R1, Weatherly H2, Kiss N3, Manca A1, Parker G2, Beresford B2, Pilkington G3, Laver Fawcett AJ3, Kanaan M2, Rabiee P1, Mann R2, Aspinal F1, 1University of York, Heslington, York, UK, 2University of York, York, UK, 3University of York, York, UK, 4Medical University of Vienna, Vienna, Austria, 5Gerald Pilkington Associates, New Malden, UK, 6York St John University, York, UK

THE VACCINE PORTFOLIO MANAGEMENT MODEL AS AN EFFICIENCY TOOL FOR JAPAN
Schecroun N1, Van Vaalender I1, Morioka Y1, Topachevskyi O1, Standaert B1, Keyrus Biopharma c/o GSK Vaccines, Wavre, Belgium, 2CHESS in Health, Ternat, Belgium, 3Japan Vaccine Co. Ltd., Tokyo, Japan, 4Digital Health Outcomes, Kiev, Ukraine, 5GSK Vaccines, Wavre, Belgium

APPLYING SYMPTOM-BASED UTILITY FUNCTIONS IN HEALTH ECONOMIC MODELLING: A CASE STUDY OF UTERINE FIBROIDS
Geale K, Hultberg M, Henriksson M, Umeå University, Umeå, Sweden, 2PAREXEL International, Stockholm, Sweden, 3Linköping University, Linköping, Sweden

QUALITATIVE DISCUSSION ON ISSUES OF PATIENT-REPORTED OUTCOME ASSESSMENT IN POST-MARKETING SURVEILLANCE FOR DISEASES IN THE ELDERLY
Akiyama S1, Watanabe Fujinuma E1, Rossi B1, Aitoku Y1, Adachi K1, Bayer Yakuhin, Ltd., Tokyo, Japan, 2Bayer Yakuhin, Ltd., Osaka, Japan

A COST-EFFECTIVE ENHANCED RETROSPECTIVE OBSERVATIONAL STUDY METHODOLOGY TO CAPTURE ECONOMIC BURDEN EVIDENCE IN A RARE DISEASE USING NON-TUBERCULOUS MYCOBACTERIA INFECTION AS A MODEL
Gallagher JR1, McDermott KJ1, Risebrough N1, Heap KJ1, Watch J1, Clarity Pharma Research, LLC, SPARTANBURG, SC, USA, 2Insmed Incorporated, Bridgewater, NJ, USA, 3ICON plc, Toronto, ON, Canada, 4ICON plc, Dublin 18, Ireland

A CONCEPTUAL SEARCH FILTER TO IDENTIFY REAL-WORLD EVIDENCE
Ogden K1, Thompson JC2, Halfpenny NJ2, Scott DA3, ICON, San Francisco, CA, USA, 4ICON Health Economics, Oxford, UK, 5ICON Health Economics and Epidemiology, Oxford, UK

METHODOLOGICAL GUIDELINES FOR ECONOMIC DRUG EVALUATION STUDIES IN PORTUGAL: MAJOR GAPS AND NEW TOPICS IN THE STUDIES EVALUATED BETWEEN 2010 AND 2014
Ramos R1, Gonçalves L1, Caldeira S1, Fernandes C1, Teixeira M1, Costa M1, INFARMED, I.P., Lisbon, Portugal

VALIDATION OF SOCIAL MEDIA ANALYSIS FOR OUTCOMES RESEARCH: IDENTIFICATION OF DRIVERS OF SWITCHES BETWEEN ORAL AND INJECTABLE THERAPIES FOR MULTIPLE SCLEROSIS
Risson Y1, Saini D1, Bonzani I2, Huisman A1, Olson M1, Novartis Pharma, Basel, Switzerland, 2IMS Health, Haryana, India, 3IMS Health, London, UK

FROM PHASE II STUDIES TO HTA SUBMISSIONS: OPTIMAL USE OF EVIDENCE FOR INFORMED DECISIONS
Karabis A1, Papadimitropoulou K1, Nikolakopoulos S1, Mapi Group, Houten, The Netherlands

FULL ECONOMIC ASSESSMENT OF ROTAVIRUS VACCINATION USING THE HEALTH ECONOMIC CAULIFLOWER TOOLBOX
Schecroun N1, Li X2, Standaert B2, Keyrus Biopharma c/o GSK Vaccines, Wavre, Belgium, 2GSK Vaccines, Wavre, Belgium

DEVELOPMENT OF A PRECIS-2 SCORING GRID: HOW PRAGMATIC ARE PRAGMATIC TRIALS OF SURGICAL AND PHARMACEUTICAL INTERVENTIONS?
Chen G, Ma Q, Costello Medical Singapore, Singapore, Singapore

CAN ADVANCES IN HEALTH MONITORS LEAD TO HEALTH BEING LOOKED AT AS A COMMODITY?
Focsa S, Executive Insight, Zug, SC, Switzerland

A METHOD TO EVALUATE UNCERTAINTY DUE TO UNKNOWN PARAMETER CORRELATION IN STOCHASTIC DECISION MODELS
O'Day K1, Liu S, Bozkaya D, Xcenda, Palm Harbor, FL, USA

PRACTICAL CONSIDERATIONS IN THE APPLICATION OF STATISTICAL METHODS FOR TREATMENT SWITCHING
Watkins CL, AstraZeneca, Macclesfield, UK
PRM271 J2 EXPLORING THE USE OF VALUE OF INFORMATION METHODS TO PRIORITISE RESEARCH TO ADDRESS THE TREATMENT UNCERTAINTIES IDENTIFIED BY THE JAMES LIND ALLIANCE PRIORITY SETTING PARTNERSHIPS
Sach T, McManus E, University of East Anglia, Norwich, UK

PRM272 J3 USE OF A MULTI-DECISION CRITERIA ANALYSIS TO SUPPORT HEALTHCARE DECISION-MAKING FOR PRIVATE Payers IN BRAZIL: DEVELOPMENT OF A MODEL TO GUIDE REIMBURSEMENT DECISIONS
D do Nascimento Junior RR1, Asano E2,1PLANSERV - Plano de Assistência à Saúde dos Servidores Públicos Estaduais, Salvador, Brazil, 2Jansen, São Paulo, Brazil

PRM273 J4 MODELLING TO DETERMINE THE PRICE AND IDENTIFY CRITICAL DATA GAPS DURING VACCINE DEVELOPMENT
Davey P, Ball M, Illuminate Health Consulting, Chatswood, Australia

PRM274 J5 HOW INSURANCE CLAIM DATA CAN HELP IN HEALTH OUTCOMES RESEARCH: AN INDIAN PERSPECTIVE
BN V1, Sawant A2, Shah C3, Bagdajuk L4, Danag A5, Velamma Medical College Hospital and Research Institute, Madurai, India, 2MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PRM275 J6 POSSIBLE APPLICATIONS OF REAL WORLD EVIDENCE IN SAFETY OPERATIONS
Kaneria J, Bhutani MK, Goyal R, Rai MK, Tata Consultancy Services, Mumbai, India

PRM276 J7 HUMAN HEALTH DAMAGE MODELLING IN LIFE CYCLE ASSESSMENT: A VALUABLE ADDITION TO THE EVALUATION OF MEDICAL INTERVENTIONS?
Debaveye S1, De Soete W2, De Meester S3, Vandijck D4, Heirman B5, Kavanagh S6, Dewulf J7, Ghent University, Gent, Belgium, 1Johnson & Johnson, Beerse, Belgium

PRM277 J8 MOVING BEYOND THE PICOS: APPROPRIATE COMPARATIVE OBSERVATIONAL DATA SELECTION CAN FACILITATE META-ANALYSIS OF RELATIVE TREATMENT EFFECTS
Sallum R1, Zhang Y2, Xu Y3, Evidera, Lexington, MA, USA, 1Evidera, London, UK

PRM278 J9 PUBLIC CONSULTATIONS: A TOOL FOR THE INCLUSION OF SOCIETY IN THE BRAZILIAN HTA PROCESS
Silva AS1, DA Silveira LC, Brazilian Ministry of Health, Brasilia, Brazil

PRM279 J10 ASSESSING HETEROGENEITY ACROSS GROUPS OF CLINICAL TRIALS BASED ON AGGREGATE DATA
Schmidt H1, Koegler H2, Geier S3, Glaab T4, Metzdorf N5, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany, 1Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

PRM280 J11 VALUE-BASED PRICING SCHEME FOR NEW TECHNOLOGY IN CONSIDERATION OF COST-EFFECTIVENESS DOMINANCE TO THE CONTROL
Kamae I1, Sugimoto T2, Yamabe K3, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 1Takeda Pharmaceutical Company Ltd., and The University of Tokyo, Tokyo, Japan

PRM281 J12 HTA STUDIES FOR MEDICAL DEVICES INCORPORATING THEIR MORAL AGEING
Kamensky V1, Rogalewicz V, Fortova B, Simackova J, Nepeko P, Czech Technical University in Prague, Kladno, Czech Republic

PRM282 J13 CLINICAL MULTI-CRITERIA DECISION ASSESSMENT (CMDA): A PROPOSAL FOR APPLYING MCDA TO COMPARE TREATMENTS IN A SIMULTANEOUS, TRANSPARENT AND OVERALL WAY
Migliore A1, Piaggio T2, Integlia D3, S.Pietro Fatebenefratelli Hospital, rome, Italy, 1Sanofi Aventis, Milan, Italy, 2ISHEO, Rome, Italy

PRM284 J14 PREVENTION AND TREATMENT OF MISSING DATA IN REAL WORLD RESEARCH
Gemmen E1, Quintiles, Inc., Rockville, MD, USA

PRM285 J15 SUGAMMADEX: THE RIGHT OPTION FOR THE EFFICIENCY OF THE OPERATING ROOM? A METHODOLOGY FOR COST / BENEFIT ANALYSIS IN COMPARISON TO THE ROUTINE CHOICE FOR REVERSAL
Ronco GL1, Emmonos S.A., Fenegro1, Italy

DISEASE-SPECIFIC STUDIES

INDIVIDUAL'S HEALTH - Clinical Outcomes Studies

PIH1 J6 A COST-EFFECTIVENESS ANALYSIS OF HOSPITAL PHARMACIST REVIEW IN OLDER PATIENTS
Gallagher J1, O'Sullivan D2, Mc Carthy S3, Gillespie P4, Woods N5, O'Mahony D6, Byrne S7, University College Cork, Cork, Ireland, 1National University of Ireland Galway, Galway, Ireland, 2Cork University Hospital, Cork, Ireland

PIH2 J7 COMPARISON OF BAZEDOXIFENE/CONJUGATED OESTROGENS VS CURRENT THERAPIES IN THE TREATMENT OF POSTMENOPAUSAL SYMPTOMS: SYSTEMATIC REVIEW AND META-ANALYSIS

PIH4 J8 PRACTICES OF SUBSTANCE ABUSE AND RISKY SEXUAL BEHAVIOR AMONG ADAMA SCIENCE AND TECHNOLOGY UNIVERSITY UNDERGRADUATE STUDENTS IN 2012/13 ACADEMIC YEARS
Mekonnen TG1, Adama Science and Technology University, Adama, Ethiopia

PIH5 J9 EXAMINING PRESCRIBING PATTERNS IN OLDER PATIENTS WITH ACUTE ILLNESS
**INDIVIDUAL’S HEALTH - Cost Studies**

**PIH6 J20**
VEHICLE D® ORAL CONTRACEPTION USE: 3-YEARS BUDGET IMPACT ANALYSIS FOR THE NATIONAL HEAL SYSTEM IN PORTUGAL

Lopes F, Bombas T, Ambrósio P, Laires P, Merck Sharp & Dohme, Oeiras, Portugal, 1Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 2Merck Sharp & Dohme, Paço d’Arcos, Portugal

**PIH7 J21**
PREVALENCE AND INCIDENCE OF MALNUTRITION AMONG GERIATRICS POPULATION IN TURKEY

Koksal I, Guikan S, Dogukan MN, Tezcan ES, Ozcan O, Berktaş M, Social Security Institute, Ankara, Turkey, 1Yeditepe University, Istanbul, Turkey

**PIH8 J22**
PREVALENCE OF SELF-MEDICATION AND ITS REASON AMONG PHARMACY STUDENTS IN INDIA: A CROSS-SECTIONAL STUDY

Hussain S, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India

**PIH9 J23**
RISK FACTORS AND CAUSES OF INTRAUTERINE DEATH

Karácsény I, Zubor M, Pakai A, Ferenczy M, Boncz I, Brantmüller E, Gelenčsér E, Oláh A, University of Pécs, Szombathely, Hungary, 1University of Pécs, Zalaegerszeg, Hungary, 3University of Pécs, Pécs, Hungary, 4University of Pécs, Kaposvár, Hungary

**PIH10 J24** IMPLANT VERSUS ORAL CONTRACEPTION USE: 3-YEARS BUDGET IMPACT ANALYSIS FOR THE NATIONAL HEAL SYSTEM IN PORTUGAL

Lopes F, Bombas T, Ambrósio P, Laires P, Merck Sharp & Dohme, Oeiras, Portugal, 1Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 2Merck Sharp & Dohme, Paço d’Arcos, Portugal

**PIH11 J25** BEMFOLA® CAN POTENTIALLY REDUCE DRUG WASTAGE AND ASSOCIATED COSTS OF INTERTILITY TREATMENT


**PIH12 J26** COST-EFFECTIVENESS ANALYSIS OF BOTULINUM TOXIN TYPE A TREATMENT FOR CEREBRAL PALSY

Yagudina R, Kulikov A, Ugrekhelidze D, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**PIH14 J28** COST STUDY OF ASSISTED REPRODUCTIVE TECHNOLOGIES IN UKRAINE

Horbachevska K, Zalis’ka O, Maksymovych N, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

**PIH15 J29** ANALYSIS OF PREECLAMPSIA PREVENTION IN REAL PRACTICE AND THE NEED TO IMPROVE INFORMATION SUPPORT OF DOCTORS IN UKRAINE

Maksymovych N, Zalis’ka O, Horbachevska K, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

**PIH16 J30** COST-EFFICIENCY OF OF NATIONAL DRUG INFORMATION CENTER THROUGH MINISTRY OF HEALH HOTLINE CALLING SERVICES (937) IN SAUDI ARABIA: APPLICATION OF A MERCIAN MODEL


**PIH17 J31** ECONOMIC IMPACT OF TREATING CHINESE POSTMENOPAUSAL WOMEN WITH 17ß-ESTRADIOL COMBINED HORMONE REPLACEMENT THERAPY (HRT) COMPARED WITH THE ALTERNATIVE PRACTICES

Connolly M, Hu S, He J, Yang Y, Zhang L, University of Groningen, Groningen, The Netherlands, 2Shanghai Health Development Research Center, Shanghai, China, 3Abbott China, Shanghai, China

**PIH18 J32** A COST-EFFECTIVENESS EVALUATION COMPARING BIOSIMILAR BEMFOLA TO GONAL-F FOR THE TREATMENT OF INFERTILITY IN AN ITALIAN CONTEST

Ripellino C, Visentin E, Gizzo S, Bühler K, IMS Health Information Solutions Medical Research S.r.l, Milan, Italy, 1University of Padua, padua, Italy, 2Centre for Gynaecology, Endocrinology and Reproductive Medicine, Ulm and Stuttgart, Germany

**PIH19 J33** COST-EFFECTIVENESS OF NEXPLANON® (ETONOGESTREL IMPLANT) COMPARED TO OTHER REIMBURSED CONTRACEPTIVE METHODS IN FRANCE BASED ON REAL LIFE DATA

Lafluma A, Agostini A, Linet T, Robert J, Levy-Bachelot L, Godard C, Cemka-Eval, Bourg la Reine, France, 2Hôpital de la Conception, Marseille, France, 3Centre Hospitalier Loire Vendée Océan, Challans, France, 4Msd France, Courbevoie, France, 5Msd France, Courbevoie, France

**PIH20 K1** POPULATION COST-EFFECTIVENESS OF A PARENTING PROGRAM FOR THE TREATMENT OF CONDUCT DISORDERS: A MODELLING STUDY TO ASSIST PRIORITY SETTING IN AUSTRALIA

Sampaio F, Barendregt J, Feldman I, Mhaloupolos C, Uppsala University, Uppsala, Sweden, 2University of Queensland, Brisbane, Australia, 3Deakin University, Melbourne, Australia

**PIH21 K2** BIOSIMILARS, ARE THEY REALLY COST SAVING? THE CASE OF RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE IN PORTUGAL

Silverio N, Batista AR, Sequeira L, Merck SA, Miraflores, Portugal

**PIH22 K3** COST-EFFECTIVENESS OF CONJUGATED ESTROGENS/BAZEDOXIFENE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN THE UNITED STATES

Teitsson S, Bobula J, Hawes C, Moffatt M, Ohna A, Borgström F, Quantify Research, Stockholm, Sweden, Pfizer
THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING KORIFOLLITROPIN ALFA WITH GANIRELIX AND FOLLITROPIN ALFA WITH CETORELIX FOR OVARIAN STIMULATION
Krysanova V, Krysanov I, Tolkashin A, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, ²Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, ³MSD, Moscow, Russia

EXAMINING THE ECONOMIC BURDEN AND HEALTH CARE UTILIZATION OF MENOPAUSAL WOMEN IN THE U.S. MEDICAID POPULATION
Keshishian A, Wang Y, Xie L, Baser O, Yuce H, ³STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Columbia University, New York, NY, USA, ¹New York City College of Technology-CUNY / STATinMED Research, New York, NY, USA

COST-EFFECTIVENESS OF RECOMMENDED MEDICATION INTERVENTION FOR TREATMENT OF DYSMENORRHEA AND ENDOMETRIOSIS IN JAPAN SETTING
Arakawa I, Momoeda M, Osuga Y, Ota I, Tanaka E, Adachi K, Koga K, Teikyo Heisei University, Tokyo, Japan, ²St Luke International Hospital, Tokyo, Japan, ¹The University of Tokyo, Tokyo, Japan, ³Kurashiki Heisei Hospital, Okayama, Japan, ⁴Bayer Yakuhin, Ltd., Tokyo, Japan

INDIVIDUAL’S HEALTH - Patient-Reported Outcomes & Patient Preference Studies

REVIEW OF ADHERENCE MEASURES FOR USE IN PHASE IV STUDIES AND RECOMMENDATIONS FOR A NEW STANDARDIZED GENERIC MEASURE
McHorney C, Reaney M, ¹ERT, North Wales, PA, USA, ²ERT, Peterborough, UK

SYSTEMATIC REVIEW ON PERSONAL PREDICTORS OF ADHERENCE TO MEDICATION. THE CUMPLE-Q SCALE
Ruiz MA, Espinosa V, Rellán E, Shih PC, Soto J, ¹Universidad Autónoma de Madrid, Madrid, Spain, ²Pfizer Spain SLU, Madrid, Spain

PATIENT-CENTERED REASONS FOR PRIMARY NON-ADHERENCE AS DERIVED FROM THE PEER-REVIEWED LITERATURE
McHorney C, ERT, North Wales, PA, USA

A NOVEL METHOD FOR CALCULATING MEDICATION ADHERENCE TO POLY-PHARMACOTHERAPY BY LINKING GENERAL PRACTICE PRESCRIBING DATA AND PHARMACY DISPENSING RECORDS
Ágh T, Inotai A, Szilberhorn L, Culig J, Petrova G, Visnansky M, Kaló Z, Syreon Research Institute, Budapest, Hungary, ²Andrija Stampar Institute of Public Health, Zagreb, Croatia, ³Medical University - Sofia, Sofia, Bulgaria, ⁴University of Veterinary Medicine and Pharmacy in Košice, Kosice, Slovak Republic, ⁵Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

INCONSISTENCY IN THE VALUATIONS OF EUROQOL EQ-5D-5L HEALTH STATES IN CHINA WAS MORE RELATED TO INTERVIEWER AND TO INTERVIEW PROCESS THAN TO RESPONDENTS’ CHARACTERISTICS
Yang Z, Erasmus University Rotterdam, Rotterdam, The Netherlands

JAPANESE POPULATION NORMS FOR PREFERENCE-BASED MEASURES: EQ-5D-3L, EQ-5D-5L, AND SF-6D
Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S, Shimozuma K, National Institute of Public Health, Wako, Japan, ¹International University of Health and Welfare, Otawara, Japan, ²University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, ³Niigata University of Health and Welfare, Niigata, Japan, ⁴Okayama University, Okayama, Japan, ⁵Ritsumeikan University, Kusatsu, Japan

UTILITY VALUES FOR HEALTH TECHNOLOGY ASSESSMENT: LEARNING LESSONS FROM ECONOMIC MODELS OF PHARMACEUTICALS SUBMITTED TO THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)
Hamers FF, Ghabri S, Le Gales C, Rumeau-Pichon C, ¹Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France, ²Haute Autorité de Santé, Saint Denis, France, ³Cermes3, Inserm U988, Villejuif, France

VALUATION OF EQ-5D HEALTH STATES BY PHARMACY STUDENTS IN POLAND (COMPARISON OF DIFFERENT METHODS AND WITH GENERAL POPULATION)
Petryszyn P, Ekk-Ciemiakowski P, Kempa K, Staniak A, ¹Wroclaw Medical University, Wroclaw, Poland, ²Warsaw School of Economics, Warsaw, Poland

A NATIONAL EQ-5D VALUE SET FOR HUNGARY - A MODEL METHODOLOGY?
Kind P, Vokó Z, ¹HSE University, St Petersburg, Russia, ²Eötvös Loránd University (ELTE), Budapest, Hungary

TIME TRADE-OFF UTILITY VALUES IN MILD AND SEVERE PRIMARY DYSMENORRHEA
Reńcz F, Gulácsi L, Varga AN, Sziklai OR, Pintér M, Brodzsky V, Corvinus University of Budapest, Budapest, Hungary

HEALTH STATUS AND QUALITY OF LIFE AMONG NURSES

REVIEW AND COMPARISON OF EQ-5D-3L VALUATION STUDIES
Dorocińska M, ¹Zawodnik S, Hermanowski TR, Medical University of Warsaw, Warsaw, Poland

REPORTED OUTCOMES WITHIN HEALTH TECHNOLOGY ASSESSMENT DECISION MAKING: CURRENT STATUS AND IMPLICATIONS FOR FUTURE POLICY
PIH40  K20  CROSS-COUNTRY PROFILE OF ADULT CAREGIVERS
Pedersini R¹, Annunziata K², Kantar Health, Epsom, UK, "Kantar Health, Princeton, NJ, USA

PIH41  K21  EVALUATION OF INPATIENTS’ SATISFACTION IN PAFOS GENERAL HOSPITAL, CYPRUS
Protopapa M¹, Panayides N¹, Latsou D², Geitona M², Paphos General Hospital, Paphos, Cyprus, "University of Peloponnese, Athens, Greece

PIH42  K22  ENGAGING PATIENTS WITH E-CLINICAL TECHNOLOGY: INCORPORATING PATIENT PREFERENCES INTO DISEASE MANAGEMENT AND CARE
Khurana L¹, Durand E¹, Gary S¹, Otero T¹, Hall C¹, Dallabrida S², ERT, Boston, MA, USA, "PHT Corporation, Boston, MA, USA

PIH43  K23  RESULTS OF THE EQ-5D-3L VALUATION PROJECT FOR IRELAND
Reddy B¹, Walsh C², Barry M¹, Kind P³, Adams R¹, National Centre for Pharmacoeconomics, Dublin, Ireland, "University of Limerick, Limerick, Ireland, "HSE University, St Petersburg, Russia

PIH44  K24  PREFERENCES FOR USING PHONE CALLS, TEXT MESSAGING, AND EMAIL TO COMMUNICATE WITH PHYSICIANS AMONG PATIENTS WITH FOUR CHRONIC DISEASES
Khurana L¹, Durand E¹, Gary S¹, Otero T¹, Hall C¹, Dallabrida S², ERT, Boston, MA, USA, "PHT Corporation, Boston, MA, USA

PIH45  K25  PATIENT USE OF ECLINICAL TECHNOLOGY TO RESEARCH, TRACK, AND SELF-MANAGE CHRONIC DISEASE
Khurana L¹, Durand E¹, Gary S¹, Otero T¹, Hall C¹, Dallabrida S², ERT, Boston, MA, USA, "PHT Corporation, Boston, MA, USA

PIH46  K26  ALIGNING PATIENT CENTRED EVIDENCE GENERATION ACROSS THE DRUG DEVELOPMENT LIFECYCLE
Naujoks C¹, Olson M², Doogan S¹, Outteridge G², Abrahamsen C³, Novartis AG, Basel, Switzerland, "Novartis Pharma AG, Basel, Switzerland, "Kinapse, New York, NY, USA

PIH47  K27  KNOWLEDGE REGARDING HARMFUL EFFECTS OF CHILD VACCINATION AND REASONS OF NON-VACCINATION AMONG MARRIED POPULATION OF MASTUNG, PAKISTAN
ul Haq N, Ashraf M, Iqbal Q, Nasim A, Riaz S, University of Balochistan, Quetta, Pakistan

PIH48  K28  CONNECTION BETWEEN THE WAY OF PARENTING AND THE BEHAVIOR OF ADOLESCENTS IN THE LIGHT OF A SURVEY IN HUNGARY
Brantmüller É¹, Horváth O¹, Karácsony I¹, Gyuró M¹, Oláh A², Boncz I², Gelencsér E¹, Pakai A³, University of Pécs, Kaposvár, Hungary, "University of Pécs, Szombathely, Hungary, "University of Pécs, Pécs, Hungary, "University of Pécs, Zalaegerszeg, Hungary

PIH49  K29  THE IMPORTANCE OF THE COMMUNICATOR FOR AN INTEGRATED CARE PROGRAM - A COMPARATIVE PREFERENCE ANALYSIS WITH DISCRETE CHOICE EXPERIMENTS
Bethge S¹, Mühlbacher AC¹, Amelung VE², "Hochschule Neubrandenburg, Neubrandenburg, Germany, "Hannover Medical School, Hannover, Germany

PIH50  K30  EXPERIENCED VS. HYPOTHETICAL HEALTH STATES PREFERENCES USING EQ-5D 3L AND 5L VERSIONS: A NATIONAL STUDY
Reddy B¹, Walsh C², Barry M¹, Kind P³, Adams R¹, National Centre for Pharmacoeconomics, Dublin, Ireland, "Trinity College Dublin, Dublin, Ireland, "HSE University, St Petersburg, Russia

PIH51  K31  RESEARCH AND EVALUATION OF THE SELF-TREATMENT PROCESS WITH THE NON-STERoidal ANTI-INFLAMMATORY DRUGS IN THE REPUBLIC OF ARMENIA
Simonyan M, Perikhanyan A, Yerevan State Medical University, Yerevan, Armenia

PIH52  K32  ASSESSMENT OF EFFECTIVE INCENTIVES FOR BLOOD DONATIONS. HOW CAN CITIZENS BE MOTIVATED TO DONATE BLOOD?
Sadler A¹, Shi L², Bethge S¹, Mühlbacher AC¹, "Hochschule Neubrandenburg, Neubrandenburg, Germany, "Hannover Medical School, Hannover, Germany

PIH53  K33  INVESTIGATION OF THE LIVING AND ITS IMPACT TO THE PREGNANTS
Ferenczy M¹, Markovics A², Élíasz Z², Szabó L³, Boncz i², Karácsony I¹, Pakai A³, Oláh A², University of Pécs, Szombathely, Hungary, "University of Pécs, Pécs, Hungary, "University of Pécs, Zalaegerszeg, Hungary

PIH54  L1  PATIENTS’ AND HEALTH PROFESSIONALS’ PREFERENCES REGARDING INTRAVENOUS VS SUBCUTANEOUS DRUG ADMINISTRATION: A LITERATURE REVIEW
Tsiantou V¹, Athanasakis K¹, Theodoropoulou F², Kyriopoulos J³, "National School of Public Health, Athens, Greece, "Roche Hellas, Athens, Greece

PIH55  L2  THERAPEUTIC REFERENCE PRICING SYSTEM IN SLOVENIA FROM THE PATIENTS’ PERSPECTIVE
Mardetko N, Kos M, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PIH56  L3  THE OXFORD PARTICIPATION & ACTIVITIES QUESTIONNAIRE (OX-PAQ): PSYCHOMETRIC ANALYSIS
Morley D¹, Dummett S¹, Dawson J¹, Fitzpatrick R¹, Churchman DR², Kelly L¹, Jenkinson C¹, "University of Oxford, Oxford, UK, "Isis Innovation Ltd, Oxford, UK

PIH57  L4  PATIENT-REPORTED OUTCOMES IN STUDIES PUBLISHED IN 2014: WHICH DISEASE AREAS HAVE BEEN THE
MAIN FOCUS OF CLINICAL RESEARCH?
Martin A, Crystallise Ltd., London, UK

PIH58 L5 THE CONCEPTUAL FRAMEWORK AND CONTENT VALIDITY OF THE POLYCYSTIC OVARY SYNDROME PATIENT REPORTED OUTCOME (PCOS-PRO) SCALE
Reaney M1, Paty J2, Black P3, Celeste Elash CA4, Martin ML5, Eek D6, 1ERT, Peterborough, UK, 2Quintiles, Hawthorne, NY, USA, 3ERT, Pittsburgh, PA, USA, 4Health Research Associates, Inc., Seattle, WA, USA, 5Astra Zeneca, Molndal, Sweden

PIH59 L6 WHERE IS YOUR ABDOMEN? PATIENT-REPORTED ABDOMEN LOCATIONS AND IMPLICATIONS FOR PATIENT-REPORTED OUTCOME ASSESSMENTS
Cala ML1, Witherspoon B1, Evans C1, Dallabrida S2, 1Endpoint Outcomes, Boston, MA, USA, 2ERT, Boston, MA, USA

PIH60 L7 USABILITY TESTING OF AN INTEGRATED GLUCOMETER AND HANDHELD ELECTRONIC PATIENT-REPORTED OUTCOME SYSTEM
Khurana L1, Durand E1, Gary S1, Otero T1, Hall C1, Dallabrida S2, 1ERT, Boston, MA, USA, 2PHT Corporation, Boston, MA, USA

PIH61 L8 COMPARISON OF PATIENT-REPORTED OUTCOMES REQUIREMENTS IN MEDICAL GUIDELINES FOR PAIN, MIGRAINE, RHEUMATOID ARTHRITIS, AND SYSTEMIC LUPUS ERYTHEMATOSUS: EUROPE VS. UNITED STATES
Burgess SM1, Gauthier M2, Cala ML3, 1Strategic Outcomes Services, Mission Viejo, CA, USA, 2Endpoint Outcomes, Boston, MA, USA

PIH62 L9 CAPTURING EMOTIONAL CONCEPTS DURING CONCEPT ElicitATION
Forbes D1, Saunders D2, Cole JC3, 1The Forbes Consulting Group, Lexington, MA, USA, 2PPD, San Diego, CA, USA

PIH63 L10 INADEQUATE TREATMENT OF POST-SURGICAL PAIN MAY RESULT IN EXTENDED HOSPITALIZATION PERIOD
Ferreira CN1, Santana CF1, Paloni Ed2, Paiva EC2, Fahham L3, Ribeiro AP1, Mazza DD4, Pfizer, São Paulo, Brazil, 1Orizon, Barueri, Brazil, 2Sense Company, São Paulo, Brazil, 3Universidade Federal de São Paulo, São Paulo, Brazil

PIH64 L11 SATISFACTION WITH LIFE OF GENERAL POPULATION OF PAKISTAN. A NATION WIDE SURVEY
Akram A1, ul Haq N2, Riaz S3, Ahmed N4, Hamid R5, 1University of Balochistan, Quetta, Pakistan, 2University of Milan, Milan, Italy

PIH65 L12 DIFFERENTIALS IN CONTRACEPTIVE USE AMONG CURRENTLY MARRIED WOMEN BY SOCIO-DEMOGRAPHIC CHARACTERISTICS IN WESTERN KENYA
Mogere DM, Great Lakes University of Kisumu, Kisumu, Kenya

PIH66 L13 STUDENTS' KNOWLEDGE AND PERCEPTIONS TOWARDS QUALITY USE OF MEDICINES: A DESCRIPTIVE ANALYSIS FROM UNIVERSITI SAINS MALAYSIA
Verma AK1, Hassali MA2, Saleem F3, Aljadhey H4, 1School of Pharmaceutical Sciences, Penang, Malaysia, 2Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, 3King Saud University, Riyadh, Saudi Arabia

PIH67 L14 ASSESSMENT OF THE ASSOCIATION BETWEEN SLEEP BEHAVIORS AND EXPERIENTIAL OUTCOMES AMONG A MULTINATIONAL ADULT POPULATION
Claeys C, Tomaszewski K, Radley C, KJT Group, Inc., Honeoye Falls, NY, USA

PIH68 L15 VALIDITY AND RESPONSIVENESS OF PREFERENCE BASED MEASURES: A CRITICAL OVERVIEW OF REVIEWS
Finch AP, Brazier J, Mukuria CW, University of Sheffield, Sheffield, UK

PIH69 L16 LINGUISTIC VALIDATION OF THE EMPHASIS-10 QUESTIONNAIRE: A PATIENT-REPORTED OUTCOME INSTRUMENT FOR ASSESSING QOL IN PULMONARY HYPERTENSION (PH)
Foster E1, Guillem A2, Lara K3, Oh P4, Popielnicki A5, Walker G6, Yorke J7, 1TransPerfect, Atlanta, GA, USA, 2Glilead Sciences, Inc., Foster City, CA, USA, 3TransPerfect, Boston, MA, USA, 4The Christie NHS Foundation Trust, Manchester, UK

PIH70 L17 PROMIS® PHYSICAL FUNCTION MULTILINGUAL TRANSLATIONS: PROGRESS AND OUTLOOK
Parks-Vernizzi E1, Correa H2, Arnold B3, Cella D4, FACITtrans, Elmhurst, IL, USA, 1Northwestern University Feinberg School of Medicine, Chicago, IL, USA

PIH71 L18 EXAMINATION OF STRESS AND PSYCHOSOMATIC SYMPTOMS IN TERMS OF NURSES' QUALITY OF LIFE
Szebeni-Kovács G1, Németh J1, Oláh A2, Boncz I3, Fullér N4, Szunomár S5, Müller A6, Pakai A7, 1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

PIH72 L19 HEALTH-RELATED QUALITY OF LIFE OF PEOPLE FROM LOW-INCOME FAMILIES IN HONG KONG, CHINA
Lam CL, Guo V, Wong CK, Yu EY, Fung CS, 1The University of Hong Kong, Hong Kong, Hong Kong

PIH73 L20 TEA CONSUMPTION AND HEALTH-RELATED QUALITY OF LIFE IN ELDERLY ADULTS
Wang P, National University of Singapore, Singapore, Singapore

PIH74 L21 HAEMODIALYSIS VERSUS NON-DIALYSIS THERAPY AMONG OLDER ADULTS WITH STAGE 5 CHRONIC KIDNEY DISEASE: A COMPARISON OF HEALTH-RELATED QUALITY OF LIFE
Ch'ng AS1, Chen LL2, Lim SK3, Poi PJ4, 1Hospital Kuala Lumpur, Kuala Lumpur, Malaysia, 2Singapore General Hospital, Singapore, Singapore, 3University of Malaya, Kuala Lumpur, Malaysia

INDIVIDUAL'S HEALTH - Health Care Use & Policy Studies
PIH75 L22 CONTRAACEPTION PATTERNS IN FRANCE: A REAL-WORLD DATABASE ANALYSIS
Agostini A¹, Godard C², Laurendeau C³, Benmahmoud A⁴, Lafuma A⁵, Doz M⁶, Levy-Bachelot L⁷, Linet T¹, Hôpital de la Conception, Marseille, France, ²MSD France, Courbevoie, France, ³Cemka-Eval, Bourg la Reine, France, ⁴MSD France, COURBEVOIE, France, ⁵Cemka-Eval, Bourg la Reine, France, ⁶Cemka-Eval, Bourg le Reine, France, ⁷Centre Hospitalier Loire Vendée Océan, Challans, France

PIH76 L23 CHILDREN'S MEDICATION IN THE NORDIC COUNTRIES – SURVEY ON NATIONAL ADMINISTRATIVE REGISTER DATA
Långström D¹, Iso-Mustajärvi i¹, Sandler N¹, Prami T², Pharmaceutical Sciences Laboratory, Åbo Akademi University, Turku, Finland, ²EPID Research, Espoo, Finland

PIH77 L24 ANTI-DEMENTIA MEDICINE DISPENSING PATTERNS: A COMMUNITY PHARMACY DATABASE ANALYSIS
Truter J¹, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa

PIH78 L25 INAPPROPRIATE DRUG PRESCRIPTION: STILL ON-GOING AMONG MALAYSIAN OLDER ADULTS
Kashyap M¹, Rajagopal SR, Loon Ek, Moon GP, Sunderajan D, AIMST University, Semeling, Malaysia

PIH79 L26 CHARACTERISTICS OF GERIATRIC PATIENTS DIAGNOSED WITH MULTIPLE SCLEROSIS TAKING DISEASE MODIFYING AGENTS IN THE UNITED STATES
Greene N¹, Greene M², MCPHS University, Medford, MA, USA, ³Georgia State University, Medford, MA, USA

PIH80 L27 ROLE OF PUPPET PLAYS IN IMPROVING CHILDREN'S KNOWLEDGE ABOUT HAND WASHING AND USING NORMAL SALINE TO RINSE NOSE AND THROAT
Mohammadhosseini N¹, Abdolghaffari AH¹, Mohebi S², Mahdaviani P³, National Committee on Rational Drug use, Tehran, Iran, ²Tehran University of Medical Sciences, Tehran, Iran, ³FASA University of Medical Sciences, Fasa, Iran

PIH81 L28 THE DRIVERS OF FACILITY-BASED IMMUNIZATION PERFORMANCE AND COSTS. AN APPLICATION TO MOLDOVA
Maceira D¹, Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

PIH82 L29 PSYCHIATRIC HEALTHCARE UTILIZATION AND RELATED COSTS IN NEWLY DIAGNOSED INDIVIDUALS WITH AUTISM SPECTRUM DISORDER (ASD) IN QUEBEC (CANADA)
Perreault S¹, Croteau C¹, Mottron L¹, Tarride J¹, Dorais M¹, Université de Montréal, Montreal, QC, Canada, ²Université de Montréal, Montreal, QC, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴StatSciences Inc, ND Ile-Peरrot, QC, Canada

PIH83 L30 VALUE ASSESSMENT FOR GENETIC TESTING OF DRUG VARIATION IN AN ELDERLY POPULATION
Biskupiak JE¹, Biltaji E¹, Bress A¹, Unni S¹, Ye X¹, Yu B¹, Mamiya T², Brixner D³, ¹University of Utah, Salt Lake City, UT, USA, ²Genelex, Inc, Seattle, WA, USA, ³University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA

PIH84 L31 STIMULANT USE AND CARDIOVASCULAR RISK AMONG CHILDREN AND ADOLESCENTS WITH ADHD: WHAT PRODUCT LABELING DOES, OR DOES NOT, TELL US
Palasik B¹, Sieluk J¹, dosReis S¹, Doshi P¹, ¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland School of Pharmacy Graduate School, Baltimore, MD, USA

PIH85 L32 THE ANALYSIS OF TELEMEDICINE TECHNOLOGIES IN PEDIATRIC PATIENTS
Namazova-Baranova L¹, Vishneva E¹, Antonova E¹, Smirnov V¹, Suvorov R², Smirnov I², Molodchenkov A³, ¹Scientific Centre of Children Health, Moscow, Russia, ²The Institute for system analysis of Russian Academy of Sciences, Moscow, Russia

PIH86 L33 THE 3-ARM STRATEGY FOR READMISSION PREVENTION: AUTOMATED PREDICTIVE MODELING, READMISSION PREVENTION INTERVENTION, AND MONITORING
Shadmi E¹, Flaks-Manov N², Kay C³, Lieberman N⁴, Balicer RD⁵, ¹University of Haifa, Haifa, Israel, ²Clalit Research Institute, Tel-Aviv, Israel, ³Clalit Health Services, Tel-Aviv, Israel, ⁴Clalit Health Services, Tel Aviv, Israel, ⁵Clalit Research Institute, Tel Aviv, Israel

PIH87 M1 PATIENTS EXPERIENCE AT HOSPITAL DISCHARGE AND READMISSIONS
Flaks-Manov N¹, Shadmi E¹, Kay C¹, Bloomenthal S², Balicer R², Clalit Research Institute, Tel-Aviv, Israel, ¹University of Haifa, Haifa, Israel, ²Clalit Health Services, Tel-Aviv, Israel, ³Clalit Health Services, Tel Aviv, Israel, ⁴Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel

PIH88 M2 THE ASSOCIATION OF EARLY EXPOSURE TO PHENOLS AND NEURO-BEHAVIOR DEVELOPMENT IN SCHOOL-AGED CHILDREN
WANG I¹, Chen M², Chen P³, National Taiwan University/Taipei City Hospital, Jen-Ai branch, Taipei, Taiwan, ²National Taiwan University, Taipei, Taiwan

PIH89 M3 SOCIOECONOMIC BURDEN OF AUTISM IN CHILDREN IN GREECE
Vourda A¹, Getlona M, University of Peloponnesse, Corinth, Greece

PIH90 M4 DETERMINANTS OF WOMEN’S CHOICE OF PLACE OF INTRAPARTUM CARE IN UGANDA: AN ANALYSIS OF SECONDARY DATA FROM UDHS
Kigenyi O¹, Makerere University, Kampala, Uganda

PIH91 M5 EXAMINATION OF KNOWLEDGE ABOUT HPV INFECTION AMONG MOTHERS AND DAUGHTERS
Pakai A¹, Millei K¹, Boncz I, Máté O², Horváthné Kívés Z³, Szabó-Gabara K³, Karácsony I³, Vajda R³, ¹University of Pécs,
NEUROLOGICAL DISORDERS - Clinical Outcomes Studies

PND1 M7 INDIRECT COMPARISON OF ONABOTULINUM VS. ORAL TRIPTANS FOR THE PHROPHYLAXIS TREATMENT OF CHRONIC MIGRAINE

fernandez Santos J, Nextium, Maidenhead, UK

PND2 M8 36 MONTHS PANGAEA: A 5-YEAR NON-INTERVENTIONAL STUDY OF SAFETY, EFFICACY AND PHARMACOECONOMIC DATA FOR FINGOLIMOD PATIENTS IN DAILY CLINICAL PRACTICE

Ziemssen T1, Albrecht H1, Haas J1, Kloet L1, Lang M1, Laske C2, Schmidt S1, Tackenberg B1, Cornelissen C3, University Clinic Carl Gustav Carus, Dresden, Germany, 2Praxis für Neurologie München, Munich, Germany, 3Jüdisches Krankenhaus Berlin, Berlin, Germany, 4Uniklinik Münster, Münster, Germany, 5NTD study group, Ulm, Germany, 6Neurologische Gemeinschaftspraxis Kassel und Vellmar, Kassel, Germany, 7NTD study group, Bonn, Germany, 8Philipps-Universität Giessen und Marburg, Marburg, Germany, 9Novartis Pharma GmbH, Nuremberg, Germany

PND3 M9 TWENTY-YEAR TRENDS AND TREATMENT OF ALZHEIMER'S DISEASE

Hanna ML1, Pickering MK1, Albrecht J2, Oehrlein EM1, Patterson CR2, Musallam A2, Perfetto EM1, University of Maryland, School of Pharmacy, Baltimore, MD, USA, 2University of Maryand, School of Medicine, Baltimore, MD, USA, 3OptumLabs, Cambridge, MA, USA, 4and Senior Vice President, Strategic Initiatives, National Health Council, Washington, MD, USA

PND4 M10 THE BURDEN OF ILLNESS OF CONGENITAL ADRENAL HYPERPLASIA IN THE UNITED KINGDOM: A RETROSPECTIVE, OBSERVATIONAL STUDY

Jenkins-Jones S1, Whitaker MJ1, Holden SE1, Morgan CL2, Ross RJ2, Currie CJ2, Pharmatelligence, Cardiff, UK, 1University of Sheffield, Sheffield, UK, 2Cardiff University, Cardiff, UK

PND5 M11 IDENTIFICATION OF CHROMOSOMAL ALTERATION AND ASSOCIATION STUDY OF MTHFR GENE MUTATIONS IN AUTISM

Arun M1, Balamuralikrishnan B2, Suresh Kumar S1, Dharwadkar SN2, Sasikala K1, Balachandar V1, Bharathiar University, Coimbatore, India, 2Bharathiar University, coimbatore, India, 3K.L.E Society, Nijalingappa College, Bengaluru, India

PND6 M12 A STUDY ON CYTOGENETIC ANALYSES AND MECP2 MUTATION WITH DOPAMINE AND SEROTONIN IN RETT SYNDROME (RTT)

Balachandar V1, Sankar K1, Jayalakshmi R1, Kamalakannan S1, Dharwadkar SN2, Sasikala K1, Arun M1, Bharathiar University, Coimbatore, India, 2K.L.E Society, Nijalingappa College, Bengaluru, India, 3BHMG, Coimbatore, India

PND7 M13 THE EFFECTIVENESS OF CBL GENE MUTATION TEST FOR DIAGNOSIS IN JUVENILE MYELOMONOCYTIC LEUKEMIA: SYSTEMATIC REVIEW

Kim SY1, Sul AR1, National Evidence-based Collaborating Agency, Seoul, South Korea

PND8 M14 CONFIRMED DISABILITY IMPROVEMENT IN PATIENTS WITH ACTIVE MULTIPLE SCLEROSIS TREATED WITH FINGOLIMOD VERSUS BRACE: A MATCHED COMPARISON OF TREATMENTS FROM THE PANGAEA AND PEARL REGISTRY STUDIES

Alsop JC1, Cornelissen C1, Vormfelde SV2, Medin J2, Ziemssen T2, Numerus, Wokingham, UK, 1Novartis Pharma GmbH, Nuremberg, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3University Clinic Carl Gustav Carus, Dresden, Germany

PND9 M15 ADJUSTED INDIRECT COMPARISON OF ORAL MULTIPLE SCLEROSIS AGENTS

Metin H1, Huppertz H, University Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen, Germany

PND10 M16 COMPARATIVE EFFECTIVENESS USING A MATCHING-ADJUSTED INDIRECT COMPARISON BETWEEN DELAYED-RELEASE DIMETHYL FUMARATE AND FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS

Fox RJ1, Cutter G1, Chan A2, Xiao J2, Okwuokenye M1, Levison D4, Lewin J1, Edwards MR3, Marantz JL1, 1Cleveland Clinic, Cleveland, OH, USA, 2University of Alabama at Birmingham, Birmingham, AL, USA, 3Ruhr-University Bochum, Bochum, Germany, 4Biogen, Cambridge, MA, USA

PND11 M17 RANKING OF DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS

Fogarty E1, Schmitz S2, Walsh C3, Barry M1, National Centre for Pharmacoeconomics, Dublin, Ireland, 1Trinity College Dublin, Dublin, Ireland, 2University of Limerick, Limerick, Ireland

PND13 M18 EPIDEMIOLOGY AND CURRENT TREATMENT OF NEUROMYELITIS OPTICA: A SYSTEMATIC REVIEW

Likhar N1, Mothe RK1, Esam H1, Kinra G1, Shah C1, Dang A1, MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PND14 M19 VARIATION IN STATE-LEVEL VS. NATIONAL INCIDENCE IN RARE GENETIC DISEASE: A MONTE CARLO SIMULATION TO EXAMINE SAMPLING VARIATION AS A PRIMARY EXPLANATION IN CONGENITAL ADRENAL HYPERPLASIA
NEUROLOGICAL DISORDERS - Cost Studies

PND17 M22 GLATIRAMER ACETATE 40 MG/ML THREE TIMES A WEEK FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS: POTENTIAL COST BENEFITS OF A REGIMEN WITH INFREQUENT INJECTIONS WHICH MAY MINIMISE SWITCHING TO THE NEWLY-INTRODUCED FIRST-LINE AND SECOND-LINE DISEASE MODIFYING THERAPIES


PND18 M23 BUDGET IMPACT OF PERAMEMPALE FOR THE TREATMENT OF PATIENTS WITH PARTIAL-ONSET SEIZURES (POS) IN RUSSIA

Tremblay G, Patel V, Tsong WH, Forsythe A, Moiseev A, Belousov D, Eisai Inc., Woodcliff Lake, NJ, USA, Eisai LLC, Moscow, Russia, Center of Pharmacoeconomic Research LLC, Moscow, Russia

PND19 M24 COST OFFSETS ASSOCIATED WITH REBIF USE IN FIRST-LINE RRMS: AN ANALYSIS BASED ON THE COCHRANE COLLABORATION REVIEW AND REAL-WORLD PERSISTENCE DATA

Wong SL, Fuji R, Beckerman R, Eisai Serono, Inc., Billerica, MA, USA, CBPartners, New York, NY, USA

PND20 M25 REAL-WORLD DATA AND BUDGET IMPACT ANALYSIS FOR INCobotulinum TOxin A AND ONabotulinum TOxin A FOR UPPER LIMB POST-STROKE SPASTICITY AT A UK CENTRE


PND21 M26 COST OFFSET ANALYSIS OF INTERFERON BETA DISEASE MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

Beckerman R, Locklear JC, Smith NJ, Phillips AL, Maple Health Group, LLC, New York, NY, USA, Eisai Serono, Inc., Rockland, MA, USA, CBPartners, New York, NY, USA

PND22 M27 BUDGET IMPACT ANALYSIS OF BOTULINUM TOXIN TYPE A TREATMENT FOR CEREBRAL PALSY IN THE RUSSIAN FEDERATION

Yagudina R, Kulikov A, Ugrekheildze D.I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PND23 M28 BUDGET IMPACT ANALYSIS FOR PEGINTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Iannazzo S, Santoni L, Saleri C, Puma E, Vestri G, Giuliani L, Centonze D, Canonicò PL, SIHS Health Economics Consulting, Torino, Italy, Biogen, Milan, Italy, Università Tor Vergata, Rome, Italy, Università del Piemonte Orientale, Novara, Italy

PND24 M29 THE BUDGET IMPACT ANALYSIS OF ADJUNCTIVE THERAPY FOR PATIENTS WITH PARTIAL EPILEPSY

Pyadushkina E, Axentyeva M, Frolov M, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, Volgograd State Medical University, Volgograd, Russia

PND25 M30 BUDGET IMPACT ANALYSIS OF PRAMIPEXOLE EXTENDED RELEASE MONOTHERAPY IN EARLY PARKINSON’S DISEASE

Belousov D, Afanasieva E, Center of Pharmacoeconomic Research LLC, Moscow, Russia, LLC «Center of Pharmacoeconomic Research», Moscow, Russia

PND26 M31 COST OF DRUG-RELATED MONITORING REQUIREMENTS FOR GLATIRAMER ACETATE AND OTHER MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES (DMTS)

van Engen A, Wu Y, Tchoukouaha T, Aran Terol P, Gandhi SK, Quintiles Advisory Services, Hoofddorp, The Netherlands, Teva Pharmaceuticals Inc, Malvern, PA, USA, Quintiles Advisory Services, Reading, UK

PND27 M32 EXCESS COSTS ASSOCIATED WITH POSSIBLE MISDIAGNOSIS OF ALZHEIMER’S DISEASE AMONG PATIENTS WITH VASCULAR DEMENTIA IN ITALY


PND28 M33 NEWER ANTEPILEPTIC DRUGS DISPENSED BY COMMUNITY PHARMACIES: GENERIC PRESCRIBING AND COST

Truter I, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa

PND29 N1 TREATMENT COSTS AND PATTERNS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH
PND30  N2  COSTS OF ILLNESS OF MULTIPLE SCLEROSIS IN SWEDEN – A POPULATION-BASED REGISTER STUDY  

PND31  N3  HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH EPILEPSY IN TIANJIN, CHINA  
Wu J, Xu T, He X, Tianjin University, Tianjin, China

PND32  N4  THE INDIRECT COSTS OF MULTIPLE SCLEROSIS ASSOCIATED WITH ABSENTEEISM IN POLAND IN 2013  
Mocko P, Kawalec P, Jagiellonian University Medical College Institute of Public Health, Krakow, Poland

PND33  N5  AN UPDATE ON HEALTHCARE RESOURCE USE AND ECONOMIC BURDEN IN ALZHEIMER'S DISEASE IN THE UNITED STATES (US) FROM A MEDICARE SAMPLE ANALYSIS  

PND34  N6  THE COST OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS WHO DEVELOP NEUTRALIZING ANTIBODIES WHILE TREATED WITH INTERFERON BETA  
Paolicelli D, Iannazzo S, Santoni L, D’Onglia M, Direnzo V, Iaffaldano A, Puma E, Di Lecce V, Trojano M, Università degli Studi di Bari, Bari, Italy, 2SIHS Health Economics Consulting, Torino, Italy, 3Biogen, Milan, Italy

PND35  N7  THE ECONOMIC BURDEN OF BRAIN DISORDERS IN KOREA  
Kim HJ, Ho SH, Lee S, Korea National Rehabilitation Center, National Rehabilitation Research Institute, Seoul, South Korea

PND36  N8  COST IMPLICATIONS OF FURTHER LIMITING OR INCREASING GENERIC PRESCRIBING OF ANTIETEPILEPTICS IN ENGLISH AND WELSH GENERAL PRACTICES  
Murphy EM, Spain VA, Beaumont A, Cogora, London, UK

PND37  N9  REAL-WORLD ASSESSMENT OF RELAPSE, MEDICAL COSTS AND PERSISTENCY OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH SUBCUTANEOUS INTERFERON β-1A  
Phillips AL, Locklear JC, Kozma C, EMD Serono, Inc., Rockland, MA, USA, 2Independent Research Consultant, Saint Helena Island, SC, USA

PND38  N10  ANALYSIS OF EXPENDITURE IN MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES EVOLUTION BETWEEN 2004-2014 IN SPAIN  
Villoro R, Hidalgo A, Instituto Max Weber, Madrid, Spain, 4University of Castilla-La Mancha, Toledo, Spain

PND39  N11  ADAPTING THE ADPKD OUTCOMES MODEL TO PREDICT COST CONSEQUENCE IN ITALIAN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) TREATED WITH JINARC (TOLVAPTAN)  
Mennini FS, Marcellusi A, Russo S, Iorio A, Lanati EP, Robinson P, Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome, Rome, Italy, 2MA Provider Srl, Milan, Italy, 3MA Provider Srl, Milano, Italy, 4Otuska Pharmaceutical Europe Ltd, Wexham, UK

PND41  N12  COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN  
Gasche D, Restovic G, Casado V, Ramirez-Boix P, Martinez Lopez J, IMS Health, Barcelona, Spain, 2Mataro Hospital, Mataro, Barcelona, Spain, 3Biogen, Madrid, Spain

PND42  N13  EXPLORING COST-EFFECTIVENESS HETEROGENEITY BY STATE: USING STATE-LEVEL VS. NATIONAL DISEASE INCIDENCE IN NEWBORN SCREENING (NBS) COST-EFFECTIVENESS ANALYSIS OF CONGENITAL ADRENAL HYPERPLASIA (CAH)  
Alotaibi A, Alsheik M, Mahida SR, Rittenhouse B, MCPHS University, Boston, MA, USA

PND43  N14  COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SCOTLAND  
Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF, Evidera, Lexington, MA, USA, 2Biogen, Maidenhead, Berkshire, UK

PND44  N15  COST-EFFECTIVENESS OF FIRST-LINE DISEASE-MODIFYING THERAPIES (DMTS) FOR RELAPSING-REMITTING MS (RRMS)  
Soini EJ, Joutseno J, Sumelahti M, ESIOY Oy, Kuopio, Finland, 2Genzyme, a Sanofi company, Helsinki, Finland, 3School of Medicine, University of Tampere, Tampere, Finland

PND45  N16  COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN IRELAND  
Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF, Evidera, Lexington, MA, USA, 2Biogen, Maidenhead, Berkshire, UK
PND46  N17  COST-EFFECTIVENESS ANALYSIS OF GLYBERA FOR THE TREATMENT OF LIPOPROTEIN LIPASE DEFICIENCY
Han X, Ni W, University of Southern California, Los Angeles, CA, USA

PND47  N18  COST-EFFECTIVENESS ANALYSIS OF GINKGO BILOBA EXTRACT (EGB761® - TANAKAN®) FOR THE TREATMENT OF DEMENTIA IN THE CZECH REPUBLIC
Kruntoradova K1, Mandelkivova M1, Mloczal T1, VALUE OUTCOMES, Prague, Czech Republic, 2Value Outcomes, Prague, Czech Republic

PND48  N19  SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF TREATMENTS IN EPILEPSY
Lachaine J1, Laberge A2, Bibeau J2, Lambert-Obry V1, 1University of Montreal, Montreal, QC, Canada, 2CHU Sainte-Justine, Montreal, QC, Canada

PND49  N20  COST-EFFECTIVENESS OF NEW THERAPIES FOR MULTIPLE SCLEROSIS IN SPAIN
Boix B1, Figueras M1, Riera M1, Novartis Farmaceutica S.A., Barcelona, Spain, 2Freelancer, Manacor, Spain

PND50  N21  COST EFFECTIVENESS OF SODIUM OXYBATE IN TREATMENT OF CATAPLEXY IN PATIENTS WITH NARCOLEPSY IN TURKEY
Tatar M1, Tunca E2, Caglayan B1, Sarica N2, Firdin A3, 1Hacettepe University, Ankara, Turkey, 2Polar Health Economics and Policy Consultancy, Ankara, Turkey, 3UCB Pharma, Istanbul, Turkey

PND51  N22  COST-EFFECTIVENESS ANALYSIS OF PRAMIPEXOLE EXTENDED RELEASE MONOTHERAPY IN EARLY PARKINSON’S DISEASE
Belousov D1, Afanasieva E1, 1Center of Pharmacoeconomic Research LLC, Moscow, Russia, 2LLC «Center of Pharmacoeconomic Research», Moscow, Russia

PND52  N23  THE COST EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FUMARATE VERSUS INTERFERON BETA-1B IN A SWEDISH SETTING
Granfeldt D1, Björnstad Å1, Ohman S1, Björholt I1, 1Nordic health economics, Göteborg, Sweden, 2Biogen, Upplands Väsby, Sweden

PND53  N24  ABOBOTOULINUMTOXIN A IN THE MANAGEMENT OF CERVICAL DYSTONIA IN THE UNITED KINGDOM: A COST-EFFECTIVENESS ANALYSIS
Desai K1, Muthukumar M1, Abougunnin S1, Harrower T1, Dinet J2, Gabriel S3, 1Evidera, London, UK, 2Royal Devon and Exeter Foundation Trust Hospital, Exeter, UK, 3IPSEN Pharma, Boulogne-Billancourt, France

PND54  N25  COST-EFFECTIVENESS OF DIMETHYL FUMARATE TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS FROM A DANISH PERSPECTIVE
Olsen J1, Wiren Å1, Incentive Aps., HOLTE, Denmark, 2Biogen Denmark A/S, Copenhagen, Denmark

PND55  N26  A COST-EFFECTIVENESS ANALYSIS OF FINGOLIMOD VERSUS DIMETHYL FUMARATE AS A SECOND-LINE DISEASE MODIFYING TREATMENT IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS
Raikou M1, Kalogeropoulou M1, Rombopoulos G2, 1University of Piraeus, Piraeus, Athens, Greece, 2Novartis Hellas, Metamorfosis, Greece

PND56  N27  COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
Silva Miguel L1, de Sá J2, Pinheiro B2, Acosta C1, CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, 2Centro Hospitalar de Lisboa Norte, Lisbon, Portugal, 3Biogen Idec, Lisbon, Portugal

PND57  N28  COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A IN ITALIAN RELAPSING REMITTING MULTIPLE SCLEROSIS MANAGEMENT
Iannazzo S1, Santoni L2, Saleri C2, Puma E2, Vestri G2, Giuliani L1, Canonico PL3, Centonze D3, 1SIHS Health Economics Consulting, Torino, Italy, 2Biogen, Milan, Italy, 3Università del Piemonte Orientale, Novara, Italy, 4Università Tor Vergata, Rome, Italy

PND58  N29  EVALUATION OF THE BURDEN OF PARKINSON’S DISEASE IN MEDICARE AND LINKED LONG TERM CARE POPULATION
Xie L1, Tan H1, Ogbono A1, Wang Y1, Baser O2, Yuce H2, 1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Columbia University, New York, NY, USA, 3New York City College of Technology-CUNY / STATinMED Research, New York, NY, USA

PND59  N30  COST-UTILITY ANALYSIS OF PRAMIPEXOLE EXTENDED RELEASE MONOTHERAPY IN EARLY PARKINSON’S DISEASE
Belousov D1, Afanasieva E1, 1Center of Pharmacoeconomic Research LLC, Moscow, Russia, 2LLC «Center of Pharmacoeconomic Research», Moscow, Russia

PND60  N31  COST-EFFECTIVENESS OF INCOCBOTULINUMTOXIN-A WITH FLEXIBLE TREATMENT INTERVALS COMPARED TO ONABOTULINUMTOXIN-A IN THE MANAGEMENT OF BLEPHAROSPASM AND CERVICAL DYSTONIA
Tilden D, Guarnieri C, Jackson D, THEMA Consulting Pty Ltd, Pyrmont, Australia

PND61  N32  COST-UTILITY OF FINGOLIMOD COMPARED WITH DIMETHYL FUMARATE (DMF) IN HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) IN ENGLAND: COMPARISON OF A MARKOV AND DISCRETE EVENT SIMULATION MODEL
**NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies**

**PND62 N33** Differences in work productivity activity impairment in RRMS patients initiated on oral DMF or platform therapies in Europe and US

- Pike J, Jones E, Rana J, Lee A, Iyer R, Adelphi Real World, Manchester, UK, ²Biogen, Cambridge, MA, USA

**PND63 O1** The impact of increasing multiple sclerosis (MS) severity level on employment and caregiver burden

- Naoshy S, Pike J, Jones E, Watson C, Biogen, Cambridge, MA, USA, ²Adelphi Real World, Manchester, UK

**PND64 O2** Comparing resource use in Alzheimer's disease across three European countries - 18-month results of the GERAS study

- Belger M, Argimon JM, Dodel R, Haro JM, Wimo A, Reed C, Eli Lilly and Company Ltd, Windlesham, UK, ²Servei Catala de la Salut, Barcelona, France, ³Philips-University, Marburg, Germany, ⁴Santeri Sant Joan de Deu, Barcelona, Spain, ⁵Karolinska Institutet, Stockholm, Sweden

---

**PND65 O3** Adherence to inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis: A systematic literature review

- Agh T, Bodnár R, Oláh M, Márszász A, Syreon Research Institute, Budapest, Hungary, ²Heim Pál Children's Hospital, Budapest, Hungary, ³Semmelweis University, Budapest, Hungary

**PND66 O4** Comparison of compliance and discontinuation rates among MS patients treated with fingolimod and other disease-modifying therapies: A Canadian retrospective claims analysis

- Haddad P, Duquette P, Yeung M, Lamarche A, Fraelic A, Chan S, Novartis, Dorval, QC, Canada, ²Notre Dame Hospital, Montréal, QC, Canada, ³University of Calgary Multiple Sclerosis Clinic, Calgary, NS, Canada, ⁴IMS Health Canada inc., Montreal, QC, Canada

**PND67 O5** How useful are EQ-5D and ZBI in assessing the impact of caring for Alzheimer's disease patients?

- Reed C, Barrett A, Lebrec J, Dodel R, Jones RW, Vellas B, Wimo A, Argimon JM, Bruno G, Haro JM, Eli Lilly and Company Ltd, Windlesham, UK, ²Lilly Deutschland GmbH, Bad Homburg, Germany, ³Philips-University, Marburg, Germany, ⁴The Research Institute for the Care of Older People, Bath, UK, ⁵Alzheimer's Disease Clinical and Research Center, Toulouse, France, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Servei Catala de la Salut, Barcelona, France, ⁸University of Rome, Roma, Italy, ⁹Santeri Sant Joan de Deu, Barcelona, Spain

**PND68 O6** Systematic literature review of health state utility values in patients with migraine


**PND69 O7** Treatment Satisfaction with Disease Modifying Therapies in Multiple Sclerosis: A Systematic Review of Studies using the Treatment Satisfaction Questionnaire for Medication (TSQM)


**PND70 O8** A comparison of stated preferences for injectable disease-modifying treatments for multiple sclerosis: Compliant vs. non-compliant patients

- Poulos C, Kinter E, Posner J, Van Beek J, RTI Health Solutions, Research Triangle Park, NC, USA, ²Biogen, Zug, Switzerland

**PND71 O9** US RRMS patient preferences for multiple sclerosis treatments: An online survey

- Mansfield CA, Thomas N, Gebben D, Lucas M, RTI Health Solutions, Research Triangle Park, NC, USA, ²Genentech, Inc., South San Francisco, CA, USA

**PND72 O10** Preferences of patients with multiple sclerosis for attributes of disease modifying drugs in decision-making: A nominal group technique and best-worst scaling

- Kremer IE, Evers SM, Jongen PJ, Dowie J, van der Weijden T, van de Kolk I, Hiligsmann M, Maastricht University, Maastricht, The Netherlands, ²MS4 Research Institute, Nijmegen, The Netherlands, ³London School of Hygiene and Tropical Medicine, London, UK, ⁴Zuyd University, Maastricht, The Netherlands

**PND73 O11** Using a mixed methods approach to develop a discrete choice experiment in multiple sclerosis


**PND74 O12** The international development of the modified hyperphagia questionnaire

- Crawford SR, Brown TM, Fehnel SE, Doward L, Nelson L, Chen A, Kim T, Roof E, Dykens EM, RTI Health Solutions, Manchester, UK, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³Zafgen, Inc., Boston, MA, USA, ⁴Vanderbilt University, Nashville, TN, USA

**PND75 O13** Association between self-administered expanded disease severity scale (EDSS) and multiple sclerosis impact scale (MSIS-29): Results from the burden of illness in patients

---
WITH MULTIPLE SCLEROSIS IN FINLAND (DEFENSE) STUDY
Viita A\textsuperscript{1}, Hämäläinen P\textsuperscript{2}, Ruutuainen J\textsuperscript{3}, Hahl J\textsuperscript{4}, Nissinen H\textsuperscript{1}, Hakkarainen T\textsuperscript{1}, Novartis Finland Oy, Espoo, Finland, \textsuperscript{2}Masku Neurological Rehabilitation Centre, Masku, Finland, \textsuperscript{3}AT Medical Affairs Consulting Oy (Medaffcon), Espoo, Finland

PND76 O14 CHALLENGES IN TRANSLATING THE MULTIPLE SCLEROSIS INTERNATIONAL QUALITY OF LIFE (MUSIQOL) QUESTIONNAIRE IN 57 LANGUAGES
Boucher P\textsuperscript{1}, Baumstarck K\textsuperscript{2}, Acquadro C\textsuperscript{3}, Mapi, Lyon, France, \textsuperscript{4}Aix-Marseille University, Marseille, France, \textsuperscript{5}Mapi Research Trust, Lyon, France

PND77 O15 RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS INITIATED ON ORAL DMF REPORT A BETTER QUALITY OF LIFE COMPARED TO PATIENTS ON PLATFORM THERAPIES AS MEASURED BY EQ-5D
Iyer R\textsuperscript{1}, Jones E\textsuperscript{2}, Rana J\textsuperscript{1}, Petrillo J\textsuperscript{1}, Lee A\textsuperscript{1}, Pike J\textsuperscript{1}, Biogen, Cambridge, MA, USA, \textsuperscript{2}Adelphi Real World, Manchester, UK

PND78 O16 DIFFERENCES IN DISEASE SPECIFIC HRQOL IN RRMS PATIENTS INITIATED ON ORAL DMF OR PLATFORM THERAPIES IN EUROPE AND US
Iyer R\textsuperscript{1}, Pike J\textsuperscript{1}, Rana J\textsuperscript{1}, Petrillo J\textsuperscript{1}, Lee A\textsuperscript{1}, Jones E\textsuperscript{2}, Biogen, Cambridge, MA, USA, \textsuperscript{2}Adelphi Real World, Manchester, UK

PND79 O17 A SYSTEMATIC REVIEW OF THE HUMANISTIC BURDEN OF DISEASE IN PATIENTS WITH FABRY DISEASE
Parini R\textsuperscript{1}, Schiﬀmann R\textsuperscript{2}, Fotheringham i\textsuperscript{3}, Todorova L\textsuperscript{4}, San Gerardo Hospital, Monza, Italy, \textsuperscript{2}Baylor University Medical Center, Dallas, TX, USA, \textsuperscript{3}Oxford PharmaGenesis Ltd, Tubney, Oxford, UK, \textsuperscript{4}Shire International GmbH, Zug, Switzerland

PND80 O18 HEALTH-RELATED QUALITY OF LIFE IN DOUBLE-BLIND PHASE III STUDIES OF BRIVARACETAM AS ADJUNCTIVE THERAPY OF PARTIAL-ONSET SEIZURES
Borghs S\textsuperscript{1}, Elmofti S\textsuperscript{1}, UCB Pharma, Slough, UK, \textsuperscript{2}UCB Pharma, Raleigh, NC, USA

NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies

PND81 O19 DOES CRGS PROVIDE PROPER GUIDES FOR AN EFFICIENT PHARMACEUTICAL PRESCRIPTION IN ALZHEIMER PATIENTS?
Caballer-Tarazona M\textsuperscript{1}, Vivas-Conseluo D\textsuperscript{2}, Escudero-Torrella J\textsuperscript{3}, Macián-Izquierdo C\textsuperscript{1}, University of Valencia, Valencia, Spain, \textsuperscript{2}Politecnico University of Valencia, Valencia, Spain, \textsuperscript{3}Hospital General, Valencia, Spain

PND82 O20 DEVELOPMENT OF A SCREENING TOOL TO SUPPORT IDENTIFICATION OF PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
Ziemssen T\textsuperscript{1}, Simsek D\textsuperscript{2}, Lahoz R\textsuperscript{2}, Verdun di Cantogno E\textsuperscript{3}, University Clinic Carl Gustav Carus, Dresden, Germany, \textsuperscript{2}Novartis Pharma AG, Basel, Switzerland

PND83 O21 QUANTIFYING THE IMPACT OF TREATMENT ON THE PUBLIC HEALTH BURDEN OF ADPKD: A UK CASE STUDY USING THE ADPKD OUTCOMES MODEL
McEwan P\textsuperscript{1}, Bennett H\textsuperscript{1}, O’Reilly K\textsuperscript{2}, Robinson P\textsuperscript{2}, Health Economics and Outcomes Research Ltd, Monmouth, UK, \textsuperscript{2}Health Economics and Outcomes Research Ltd, Cardiff, UK

PND84 P1 MUSCULAR DYSTROPHY PATIENTS WITH SEVERE RENAL DYSFUNCTION: ANALYSIS OF ACE-INHIBITOR USE
Vlahiotis A\textsuperscript{1}, Stott-Miller M\textsuperscript{1}, Palmer LA\textsuperscript{2}, Truven Health Analytics, Cambridge, MA, USA, \textsuperscript{2}Truven Health Analytics, Bethesda, MD, USA

PND85 P2 COSTS ASSOCIATED WITH PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TAKING ONCE DAILY FINGOLIMOD CAPSULES IN THE UNITED STATES
Greene N\textsuperscript{1}, Greene M\textsuperscript{1}, MCPHS University, Medford, MA, USA, \textsuperscript{2}Georgia State University, Medford, MA, USA

PND86 P3 OVER-PRESCRIPTION OF FINGOLIMOD IN GERMANY
Schoch G, Steinme T, Tamminga M, Blank S, Würdemann E, Techniker Krankenkasse, Hamburg, Germany

PND87 P4 CHARACTERISTICS OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TAKING ONCE DAILY FINGOLIMOD CAPSULES IN THE UNITED STATES
Greene N\textsuperscript{1}, Greene M\textsuperscript{1}, MCPHS University, Medford, MA, USA, \textsuperscript{2}Georgia State University, Medford, MA, USA

PND88 P5 CHARACTERISTICS OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TAKING DISEASE MODIFYING AGENTS
Greene N\textsuperscript{1}, Greene M\textsuperscript{1}, MCPHS University, Medford, MA, USA, \textsuperscript{2}Georgia State University, Medford, MA, USA

PND89 P6 DIFFERENCES IN MULTIPLE SCLEROSIS RELAPSE RATES BASED ON PATIENT ADHERENCE, AVERAGE DAILY DOSE, AND PERSISTENCE WITH DISEASE-MODIFYING THERAPY: OBSERVATIONS BASED ON REAL-WORLD DATA
Irwin DE\textsuperscript{1}, Cappell KA\textsuperscript{2}, Davis BM\textsuperscript{2}, Wu Y\textsuperscript{2}, Grinspan A\textsuperscript{2}, Gandhi SK\textsuperscript{2}, Truven Health Analytics, Chapel Hill, NC, USA, \textsuperscript{2}Truven Health Analytics, Ann Arbor, MI, USA, \textsuperscript{3}Teva Pharmaceuticals Inc, Malvern, PA, USA, \textsuperscript{4}Teva Pharmaceuticals, Weston, FL, USA

PND90 P7 INEQUALITIES IN ACCESS TO TREATMENT FOR MULTIPLE SCLEROSIS IN ENGLAND CONTINUE DESPITE SERVICE IMPROVEMENT INITIATIVES AND POLICY REFORMS
PND91  P8  NATALIZUMAB USE IN MULTIPLE SCLEROSIS: A REAL WORLD EVIDENCE (RWE) ANALYSIS OF ITS IMPACT ON NHS RESOURCES IN ENGLAND
Horsley W1, Nayar V2, Auddy G3, NHS England, North of England Specialised Commissioning Team, Newcastle, UK, 1SVMPharma, Winchfield, UK

PND92  P9  TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS IN MUSCULAR DYSTROPHY PATIENTS: ANALYSIS USING ADMINISTRATIVE CLAIMS DATA
Stott-Miller M1, Vlahiotis A1, Palmer LA2, 1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA

PND93  P10  HEALTH CARE COSTS ASSOCIATED WITH GERIATRIC PATIENTS DIAGNOSED WITH MULTIPLE SCLEROSIS TAKING DISEASE MODIFYING AGENTS IN THE UNITED STATES
Greene N1, Greene M2, 1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA

PND95  P11  DEVELOPMENT OF MS BUDGET MANAGER: A PRACTICAL TOOL TO ASSIST ALTERNATIVE STAKEHOLDERS AT MULTIPLE DECISION LEVELS IN THE FORECAST AND FINANCIAL MANAGEMENT FOR MULTIPLE SCLEROSIS (MS)
Pradelli L, Bellone M, Zaniolo O, AdRes Srl, Torino, Italy

PND96  P12  HUMANISTIC AND ECONOMIC BURDEN OF FOCAL DRUG-REFRACTORY EPILEPSY IN EUROPE
Vrouchou P1, Risi A2, Annoni E3, Alvarez G4, Grovale N5, 1Medtronic Europe, Tolochenaz, Switzerland, 2Medtronic Europe, Rome, Italy, 3Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 4Medtronic USA, Louisville, CO, USA

PND97  P13  IMPACT OF ONGOING NATIONAL HEALTH TECHNOLOGY ASSESSMENT CHALLENGES ON PATIENT ACCESS TO NEW THERAPIES FOR MULTIPLE SCLEROSIS IN GERMANY AND THE UK
Leach N1, Kanakam N1, Droeschel D2, Walzer S2, OPEN Access Consulting, Marlow, UK, 1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany

PND98  P14  A LONG TERM ANALYSIS OF THE CLINICAL AND COST EFFECTIVENESS OF GLATIRAMER ACETATE FROM THE UK MULTIPLE SCLEROSIS RISK SHARING SCHEME
Sumra M, Walters E, Teva UK Limited, Castleford, UK

PND99  P15  COMPARISON OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) TREATED WITH DISEASE MODIFYING TREATMENTS (DMT) IN EUROPE (EU) AND THE UNITED STATES (US)
Narayanan S1, O'Meara P2, White J3, Chan J4, Hooper R5, Baynton E6, 1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, London, UK

PND100  P16  ADHERENCE TO GLATIRAMER ACETATE 40 MG VERSUS ORAL DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS
Halpern R1, Wolbeck R1, Blauer-Peterson C1, Wu Y2, Gandhi SK2, 1Optum, Eden Prairie, MN, USA, 2Teva Pharmaceuticals Inc, Malvern, PA, USA

PND101  P17  CHARACTERISTICS OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) TAKING INJECTABLE AND ORAL DISEASE MODIFYING TREATMENTS (DMT) IN EUROPE (EU)
Narayanan S1, O'Meara P2, White J3, Chan J4, Hooper R5, Baynton E6, 1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, London, UK